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Breast cancer is the most diagnosed malignancy among women in the United States. 
Approximately 70% of breast tumors express estrogen receptor (ER)-alpha and are deemed ER-
positive. ER-positive breast tumors depend upon endogenous estrogens to promote ER-mediated 
cellular proliferation. Although adjuvant endocrine therapy is an effective treatment option for 
ER-positive breast cancer, recurrence remains an unresolved issue. Studies suggest that ESR1 
ligand binding domain (ESR1-LBD) mutations and exposure to alternative estrogens may serve 
as potential mechanisms of resistance to endocrine therapy.   
 
Chapter II of this dissertation examined whether two oxidized metabolites of n-butylparaben and 
iso-butylparaben, discovered in human urine, bind to ER-alpha and promote estrogen signaling. 
The estrogenic properties of metabolites 3-hydroxy n-butyl 4-hydroxybenzoate (3OH) and 2-
hydroxy iso-butyl 4-hydroxybenzoate (2OH) were determined using the ER-positive, estrogen-
dependent breast cancer cell line MCF-7. The 3OH and 2OH metabolites induced cellular 
proliferation with EC50 of 8.2 and 2.2 µM, respectively. The expression of a pro-proliferative, 
estrogen-inducible gene (GREB1) was induced by these compounds and blocked by co-
administration of an ER antagonist. The metabolites promoted ER-dependent transcriptional 
activity of an ERE-luciferase reporter construct. 
  
Crystal structures exist for human, but not rodent, ER-alpha-LBD. Consequently, rodent studies 
involving binding of compounds to ER-alpha-LBD are limited in their molecular-level 
 xii 
interpretation and extrapolation to humans. In chapter III, we used the human ER-alpha-LBD 
structure (PDB 3UUD) as a template to produce rat and mouse homology models which were 
employed to generate docking poses of 23 Group A ligands (estradiol, diethylstilbestrol, and 21 
paraben analogs) in AutoDock Vina. Numbers of interspecies ligand-receptor residue contacts 
were highly similar: Sorensen Sc = 93.1 ± 7.5% (human-mouse) and 92.5 ± 7.1% (human-rat). 
Pyramid plots of numbers of ligand receptor atom contacts by residue exhibited high interspecies 
symmetry. Group B ligands were 15 3,5-disubstituted parabens shown to exhibit decreased 
binding to human ER-alpha and increased antimicrobial activity. Ligand efficiencies calculated 
from docking of Group B ligands into human ER-alpha-LBD were highly correlated with those 
derived from published experimental data.  
 
The most common recurring ESR1-LBD mutations, D538G and Y537S, are detected in ~30% of 
patients with metastatic breast cancer who are resistant to endocrine therapy. In chapter IV, we 
used the MCF-7 cells to develop in vitro models that express the Y537S and D538G mutants 
using CRISPR knock-in and screened novel compounds that target ER-alpha for degradation. 
Results show that compound ERD-148 attenuated ER-dependent growth with IC50 values of 0.8, 
10.5, and 6.1 nM in wildtype MCF-7, Y537S, and D538G cells respectively. MCF-7 cells treated 
with ERD-148 for 24 hours show lower levels of ER-alpha protein expression compared to 
mutant cells treated at 1 nM for 24 hours. GREB1 gene expression was downregulated at 




In summary, our results indicate that oxidized paraben metabolites exhibit behavior akin to weak 
estrogens. Our constructed rodent ER-alpha-LBD receptors interact with ligands in like manner 
to the human receptor, thus providing a high level of confidence in extrapolations of rodent to 
human ligand-receptor interactions. ERD-148 was shown to inhibit the growth of ER-positive 
breast cancer via antagonism of ER-alpha. Future studies are needed to determine whether 
exposure to estrogenic EDCs or the presence of ESR1 mutations contribute to a greater risk of 














Estrogen and other steroid hormones are lipophilic small molecules that are primarily 
produced in the gonads and adrenal glands [1, 2]. Steroid hormones are well known to play 
prominent roles in reproduction, organ development, and the regulation of normal physiological 
processes [3-7]. Organs and tissues such as the brain [8], lungs [1], gonads [9, 10], and breast 
[11] are just a few examples of targets which steroid hormones act upon. Some of these same 
hormones have also been shown to be critically involved in the development or progression of 
steroid hormone-dependent diseases such as prostate [12] and breast cancer [13]. For example, 
cumulative lifetime exposure to estrogens has been associated with an increased risk of breast 
cancer in postmenopausal women [13]. The importance of estrogens in breast cancer progression 
is highlighted by the fact that approximately 70% of all breast tumors express the estrogen 
receptor and proliferate in the presence of estrogenic hormones [14]. There has been increasing 
interest and debate as to whether environmental exposure to endocrine disrupting chemicals 
(EDCs) can alter normal steroid hormone regulated processes and contribute to estrogen-
dependent diseases such as breast cancer. Here, I will review the current understanding of the 
biosynthetic pathway for estrogen, the implications of suspected EDCs on altering normal human 
physiology and estrogen regulated pathways, the relationship between estrogen and breast 
cancer, acquired mechanisms of resistance to endocrine therapy, the potential role of estrogen 
mimics in breast cancer progression, and the rational for my thesis.   
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Human Physiology of Steroid Hormones  
 
Located at the base of the brain, neurons within the hypothalamus are responsible for secreting 
hormones, commonly referred to as hypophysiotropic or hypothalamic hormones, which regulate 
the function of the pituitary gland [15, 16]. Upon receiving input from the hypothalamus, the 
pituitary gland will then control the production and secretion of numerous peptide and steroid 
hormones [17], with secretion occurring specifically from anterior pituitary gland [16]. 
Hypothalamic hormones secreted from neurons of the hypothalamus first enter capillaries 
located at the junction between the hypothalamus and pituitary gland, known as the median 
eminence, and are carried to the anterior pituitary gland via the hypothalamo-hypophyseal portal 
vessels [18, 19]. Upon diffusing out of the anterior pituitary gland capillaries and into the 
interstitial fluid, hypothalamic hormones bind to specific membrane receptors to either stimulate 
or inhibit the release of anterior pituitary gland peptide and steroid hormones [20]. Some of these 
hormone pathways are directly involved in controlling the production of gonadal steroids and 
their precursors through gonadal and adrenal gland control systems [21, 22]. 
 
Adrenal Control Systems  
 
Upon receiving synaptic input from the central nervous system, the hypothalamus will secrete 
corticotropin-releasing hormone (CRH) to simulate the release of adrenocorticotropic hormone 
(ACTH) from the anterior pituitary gland [22]. ACTH secretion then acts on the adrenal cortex to 
produce cortisol which exerts negative feedback on CRH and ACTH secretion to prevent the 
overproduction of cortisol [23]. Cortisol secretion is primarily responsible for regulating 
metabolism and stress response and is a critical component of the hypothalamic-pituitary adrenal 
axis [22, 24]. In addition to cortisol production, the adrenal cortex is also responsible for 
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secreting four other major hormones all derived from cholesterol which are known as 




The adrenal cortex is comprised of three main cell layers with the outer layer being the  
zona glomerulosa (ZG), the middle layer zona fasciculata (ZF), and the interior layer called the 
zona reticularis (ZR) [25]. The ZG cells express the enzymes needed to synthesize corticosterone 
which is converted to aldosterone under the control of the hormone angiotensin II [25]. The ZF 
and ZR cells both produce cortisol and androgens, however, cortisol is primarily secreted from 
ZF cells while the ZR cells primarily secrete androgens such as DHEA and androstenedione 
[25]. Although DHEA and androstenedione are both considered weak androgens, they are not 
nearly as potent as the major male androgen hormone, testosterone, that is primarily produced in 
the testes from androstenedione [2, 26]. Similarly, estrogen is the predominant female steroid 
hormone that is produced in ovarian endocrine cells that express aromatase, the cytochrome 
P450 enzyme that converts precursor androgens to estrogens [2, 27].    
 
Gonadal Control Systems  
 
The proper control of gonadal steroid secretion from either the testes or ovarian endocrine cells 
is essential for regulating biological process such as germ cell development, reproduction, and 
sexual differentiation [28-30]. For example, the presence or absence of gonadal hormones can 
influence the formation of accessory reproductive organs in females which include breast 
development and ductal formation [11]. These gonadal hormones can also influence the 
development of secondary sex characteristics, and the external differences between males and 
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females, which consist of differences in hair distribution, body shape, and relative adult height 
[31-33]. Gonadal hormone secretion and reproductive function in both male and females is 
largely dependent upon peptide hormone signaling by gonadotropins released under the control 
of hypothalamic-pituitary gonadal axis (HPGA) [34]. To promote the synthesis of gonadal sex 
hormones, the HPGA first begins with the secretion of a hypothalamic peptide hormone known 
as gonadotropin-releasing hormone (GnRH) from the hypothalamus [35]. Secreted GnRH then 
travels to the anterior pituitary gland via the hypothalamo-hypophyseal portal vessels to induce 
the release of two gonadotropins referred to as follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH) [18, 34]. Both FSH and LH stimulate the gonads to produce and 
secrete sex hormones that also stimulate the release of GnRH from the hypothalamus and 
gonadotropins secreted from the anterior pituitary gland via a negative feedback loop [34, 36].  
 
Gonadal Steroidogenesis  
 
Testosterone and estrogen production are not unique to each biological sex. Instead, it is the 
concentration ratio of these two hormones that are very different and unique between the sexes. 
Both male and female gonadal sex hormones, similar to the steroid hormones produced in the 
adrenal cortex, are derived from the same precursor molecule, cholesterol [2]. The first step in 
gonadal steroidogenesis begins with the conversion of cholesterol to pregnenolone via the 
cholesterol side-chain cleavage enzyme (P450scc) (Figure 1.1) [2]. ZR cells of the adrenal cortex 
are able to produce large quantities of DHEA from pregnenolone and 17-hydroxypregenolone 
via the catalytic activity of the 17α-hydroxylase (P450c17) [37]. DHEA produced in the adrenal 
cortex is mainly sulfated and exists as the most abundant circulating steroid in humans, 
dehydroepiandrosterone-3-sulfate (DHEAS), sulfated by sulphotransferase 2A1 (SULT2A1) 
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[38]. Although males can produce DHEA in the testis as well adrenal cortex [39], the formation 
of DHEAS is bypassed due to the lack of SULT2A1 expression in this reproductive organ. Male 
gonadal DHEA is then converted to androstenedione by type 2 3β-hydroxysteroid dehydrogenase 
(3ßHSD2) and subsequently to testosterone by type 3 17β-hydroxysteroid dehydrogenase 
(17ßHSD3) [40] within the Leydig cells under the stimulation of LH [41]. Testosterone will then 
act on the Sertoli cells of the testis to facilitate spermatogenesis and the secretion of a peptide 
hormone, inhibin, that regulates FSH release from the anterior pituitary gland [42]. The prostate 
gland in males will also convert some testosterone to a more potent androgen, 
dihydrotestosterone (DHT), via the catalytic activity of the enzyme 5α-reductase [41]. In target 
tissues, such as the brain and adipose, testosterone may undergo irreversible aromatization to 
17ß-estradiol (E2) by the cytochrome P450 enzyme aromatase [41]. 
 In females, gonadal steroidogenesis is highly dependent upon the stage of the ovarian 
cycle as well as the cooperation of cell specific steroidogenic enzymes expressed in granulosa 
and theca cells surrounding the oocyte which together form a follicle [2]. With respect to ovarian 
stage, E2 is the primary steroid hormone produced during the follicular phase while progesterone 
is primarily synthesized during the luteal phase. In order to enzymatically synthesize E2, 
secreted LH stimulates the expression of P450scc within granulosa cells to produce 
pregnenolone which diffuses across the cellular membranes into the adjacent theca cells (Figure 
1.1) [43]. Unlike Leydig cells in males, granulosa cells do not express P450c17 and are unable to 
convert pregnenolone to DHEA and therefore must rely on the cooperation of theca cells to 
produce E2 [41]. Once pregnenolone has diffused into the theca cells, it is converted to 17-
hydroxypregenolone by P450c17 and then to DHEA by the same enzyme [41]. The newly 
formed DHEA is converted to androstenedione by 3ßHSD2 and a portion of the androstenedione 
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will be converted to testosterone. However, most synthesized androstenedione will return to the 
granulosa cells [44]. Under the control of FSH, androstenedione is converted to estrone by 
aromatase which is then converted to E2 by type 1 17β-hydroxysteroid dehydrogenase 
(17ßHSD1) within the granulosa cells [41, 44]. During the luteal phase, greater enzymatic 
activity of 3ßHSD2 in the corpus luteum leads to the increased production of progesterone from 
pregnenolone [2]. Progesterone and E2, as well as inhibin produced by the granulosa cells, exert 
negative feedback on the HPGA to decrease GnRH pulses and regulate FSH and LH secretion 
[45, 46].  
     
Transport of E2 in the Blood 
 
Due to the lipophilic nature of steroid hormones, they can readily diffuse across cellular 
membranes and into systemic circulation [47]. Unlike peptide hormones, which are generally 
highly water-soluble, steroid hormones are poorly soluble in blood due to their lipophilic nature. 
Therefore, most steroid hormones are reversibly bound to carrier proteins in the plasma which 
are in equilibrium with the free and bound state of a given hormone [48]. Albumin, sex hormone-
binding globulin, and corticosteroid-binding globulin are examples of carrier proteins that 
transport steroid hormones in the blood [49]. However, it is the unbound, or free steroid, that 
diffuse out of the capillaries to elicit their biological effects on target cells expressing their 
cognate receptors, including sex steroid nuclear receptors. 
In women, the concentration of circulating E2 varies greatly depending on the stage of 
the ovarian cycle, pregnancy, and whether normal ovarian function has ceased after menopause 
[50]. The combined concentration of bound and free circulating E2 in premenopausal woman 
with normal ovarian function can vary considerably from 73pM – 1600pM and as high as 26nM 
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during pregnancy [51-53] while in men the standard range of E2 is 36pM – 305pM [54]. During 
menopause, the ovaries no longer respond to gonadotropins released by the HGPA. As a result, 
the production of E2 and inhibin from the ovaries decreases and these hormones are less able to 
exert negative feedback on FSH and LH secretion. However, the peripheral aromatization of 
adrenal androgens by aromatase maintain circulating concentration of E2 in postmenopausal 
women albeit at much lower concentrations (<47pM) compared to premenopausal women [55]. 
Yet, this low E2 concentration is not able to sustain regular physiologic function of estrogen-
dependent tissues such as the breasts and genital organs. Atrophy of these tissues is common 
during menopause and is associated with an increased risk of coronary artery disease and 
osteoporosis, a decline in bone mineral density [56]. These physiological phenomena observed in 
postmenopausal women highlight the apparent protective effect of E2 and is the reason why 
hormone replacement therapy (HRT) is prescribed to many women [57]. Despite the potential 
health benefits of HRT in women, its use is limited due to the fact that long-term exposure of E2 
is associated with an increased risk for endometrial and breast cancer [13, 55, 58]. Tumor cell 
proliferation in these two cancer types is generally maintained from the estrogen binding to and 
activating its cognate nuclear receptor.  
 
Nuclear receptors  
 
Nuclear receptors are a class of transcription factors that regulate gene expression and modulate 
various physiological properties upon binding to their specific receptor ligands [59]. Ligand-
binding to their nuclear receptor induces a conformational change that leads to transcriptional 
activation in order to achieve a biochemical response [60]. Sex hormones are examples of 
ligands known to promote both genomic or non-genomic actions upon binding to their cognate 
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receptor [61]. For example, the estrogen receptor (ER) and the androgen receptor (AR) are two 
nuclear receptors that have been reported to utilize genomic or non-genomic signaling pathways 
[60, 62-64]. There are at least 48 known genes encoding for nuclear receptors in humans [59]. 
The remainder of this chapter, however, will focus primarily on estrogen signaling and its 
relationship to the concept of endocrine disruption and ER-dependent breast cancer. 
 




There are two main subtypes of ER known as estrogen receptor α (ERα) and estrogen receptor ß 
(ERß) (Figure 1.2) [65]. The first reports of the cloning and sequencing of ERα occurred in 1986 
by two separate groups (Green et al., 1986; Greene et al., 1986) [66, 67], while Kuiper et al. 
were the first to clone and identify ERß from rat prostate several years later in 1996 [68]. Recent 
reports have identified at least five isoforms of ERß that further add to the complexity of the 
possible regulatory roles of ERß [69]. However, most research groups do agree that ERß 
primarily exhibits antiproliferative, pro-apoptotic, and tumor suppressive functions by opposing 
and antagonizing ERα mediated pathways [70-73]. It has been suggested that ERß achieves these 
opposing actions by sequestering E2 or by forming heterodimers with ERα to exert a negative 
regulatory effect on ERα function [74, 75]. Despite these findings, major issues with the cell 
lines and inadequately validated antibodies for ERß were recently described [76]. Nelson et al. 
showed that one of the main antibodies used to detect ERß, NCL-ER-BETA, is non-specific for 
this receptor [76]. Using antibodies verified by liquid chromatography–mass spectrometry, 
Nelson et al. also showed that ERß was not expressed in either MCF-7 or LNCaP cell lines 
which have been commonly used to study ERß and potentially calls into question some of the 
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conclusions made in studies using NCL-ER-BETA antibody [76]. The findings by Nelson et al. 
likely explain much of the uncertainty and inconsistencies regarding the role of ERß in breast 
and prostate cancer [77] and contributes to the rationale for this chapter focusing on ERα in the 




For ERα, at least three isoforms have been reported with molecular weights of 36 (ERα36), 46 
(ERα46), and 66 kDa (ERα66) [66, 67, 78, 79]. ERα66 is a nuclear receptor and transcription 
factor that is primarily localized to the cellular nucleus and is comprised of six unique domains 
that serve separate functions [66, 67, 80] (Figure 1.2). The A/B domain includes the region of the 
receptor known as activation function–1 (AF-1) that contains a serine residue at position 118 
(Ser118). Phosphorylation of Ser118 (ERα-P-Ser118) has been shown to be critical for proper 
function of ER where this receptor modification is likely controlled in part by the mitogen-
activated protein kinase pathway, with CDK7 or IKK-α [81-83]. Weitsman et al. used chromatin 
immunoprecipitation to show that ERα-P-Ser118 binds to known ERα coactivators proteins, 
specifically p300 and steroid receptor coactivator-3 [84], to provide evidence of the functional 
involvement of ERα-P-Ser118 in estrogen regulated pathways [82]. The DNA binding domain 
(DBD) is in the C domain of ERα66 and is responsible for binding to the estrogen response 
element (ERE) located at the promotor region of estrogen regulated genes. The interaction of the 
DBD with an ERE occurs through recognition of the consensus palindromic sequence identified 
as GGTCAnnnTGACC [85, 86]. Additionally, the D domain hinge region has been implicated in 
the recruitment of transcription factors such as c-Jun and contains the nuclear localization 
sequence which aids in the translocation of ERα to the nucleus [87].  
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 The ligand binding domain (LBD) and activation function-2 (AF-2) region of ERα66 are 
both located in the E domain of this receptor (Figure 1.2). However, the functions of the LBD 
and AF-2 of ERα66 are primarily activated upon binding of endogenous estrogens [80, 88]. 
Brzozowski et al. were the first to report the crystal structure for the LBD of ERα66 in complex 
with E2 using x-ray diffraction [89]. They noted that the helical arrangement of ERα66 formed a 
hydrophobic ligand binding cavity that complemented the lipophilic characteristic of E2. The 
shape of this binding site cavity appeared to favor the formation of specific hydrogen bonds with 
E2 which are key to orienting the bound hormone [80, 89]. The binding of a high affinity agonist 
such as E2 induces a conformational change in ER that stabilizes the positioning of helix 12 
(H12) which has been shown to be a critical LBD helix whose positioning directly influences the 
transcriptional activity of ERα66 [88]. The stabilization of H12 exposes a hydrophobic grove 
between helices H3, H4, and H12 that recognizes and recruits coactivators that contain LxxLL 
helical motifs to the AF-2 region [88, 90, 91]. In contrast, the binding of antagonists destabilizes 
the positioning of H12 which prevents LxxLL coactivator association with ER and favors the 
recruitment of transcriptional corepressors as observed with the ER antagonist tamoxifen and its 
more potent metabolite, 4-hydroxytamoxifen [92, 93]. The final domain of ERα66 is known as 
the F domain which has been suggested to be involved in modulating the positioning of H12 and 
activity of ERα66 (Figure 1.2) [94, 95]. Targeted mutations of the F domain have been shown to 
alter the affinity of E2 and ER antagonists such as tamoxifen or even preventing the interaction 
of some coactivator proteins [96-99]. 
 
Other ERα Isoforms and GPR30 
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The ERα46 isoform was first cloned by Flouriot et al. in 2000 with ERα36 first identified by 
Wang et al. in 2005 [79, 100]. Alternative splicing of the ESR1 gene likely explains why ERα46 
isoform completely lacks the AF-1 domain while the rest of the receptor is mostly identical to 
ERα66 [101]. However, ERα36 is a truncated isoform that lacks both the AF-1 and AF-2 domain 
observed in ERα66 [101] (Figure 1.2). Interestingly, Flouriot et al. reported that ERα46 may 
form heterodimers with ERα66 to regulate genomic estrogen signaling mediated by the AF-1 
domain of ERα66 [79]. In contrast to ERα46, ERα36 has been described as being predominantly 
a membrane associated isoform of ER that may function to inhibit the estrogen-dependent 
transactivation of ERα66 [102]. However, the exact mechanism by which ERα36 inhibits 
genomic estrogen signaling remains unclear. Both ERα36 and ERα46 retain the ability to 
dimerize and contain intact DBD which allows these isoforms to interact with and compete for 
same EREs that ERα66 normally associates with [103]. Much of the published work studying the 
shorter ERα isoforms relied on immunohistochemistry techniques that have limited ability to 
effectively distinguish between different ERα isoforms due to the lack of isoform specific ERα 
antibodies [75]. To date, the specific interaction and roles of each of these ERα isoforms in the 
context of E2-induced cell proliferation remains unclear and controversial. 
 GPR30 is a G-protein-coupled membrane receptor that was first reported by Owman et 
al. in 1996 and was named GPR30 in 1997 [104, 105]. The exact cellular localization of GPR30 
has been controversial due to multiple reports stating that GPR30 is only localized to the plasma 
membrane while others have claimed that it is an intracellular membrane protein located on the 
endoplasmic reticulum [106, 107]. The role of GPR30 as an estrogen receptor has also received 
skepticism due to conflicting reports on whether or not E2 binds to GPR30 [106-109]. Otto et al. 
conducted an in vivo study using GPR30 deficient mice and concluded that GPR30 was not 
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required for mediating the effect of E2 on reproductive target organs in murine models [110]. 
Pedram et al. used endothelial cells from ERα/ERß deficient mice (DERKO mice) and showed 
that E2 did not bind to these cells nor was E2 signaling pathways activated in these cells as 
determined by extracellular-signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K) 
expression [111]. In contrast to endothelial cells from DERKO mice, wild type endothelial cells 
readily bind to E2 with and exhibit increased ERK and PI3K stimulation even though both cell 
types expressed similar levels of GPR30 [111]. Pedram et al. also used small interfering RNA 
(siRNA) directed to GPR30 and showed that rapid E2 signaling was not affected in MCF-7 cells 
whereas siRNA to ERα prevented these effects [111]. The findings by Otto et al. and Pedram et 
al. are just a few examples that highlight the importance of classical ERs as well as the need to 
clarify the potential role of GPR30 in the context of estrogen signaling. 
Due to the significant knowledge gaps with the shorter ERα isoforms and inconsistencies 
regarding the GPR30 membrane receptor [112], the remainder of this chapter will focus on the 
ERα66 isoform. All following discussions of ERα will refer to the ERα66 isoform which is an 
important biological target in the context of endocrine disruption including its well-established 
role in breast cancer as described in the following sections. 
 
Environmental Estrogens and Anti-androgenic Endocrine Disrupting Compounds 
 
The field of endocrine disruption and the concern that environmental exposures may contribute 
to adverse health effects was pioneered by the American marine biologist, author, and 
conservationist Rachel Carson (1907 – 1964). In 1962, Carson’s book Silent Spring raised 
concerns about the widespread use of the pesticide dichlorodiphenyltrichloroethane (DDT) in the 
late 1950s and its potential harm to ecosystems and human health [113, 114]. Carson’s book 
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immediately gained national attention both from the public and the US government. In 1970, the 
US government established the United States Environmental Protection Agency (US EPA) with 
the authority to implement regulations designed to protect the environment and human health 
[113]. In 1972, the US banned the use of DDT over concerns that it was associated with an 
increase in reproductive abnormalities observed in fish and wildlife as well as its ability to 
biomagnify within adipose tissue of higher species of the ecosystem [115]. Although the 
widespread environmental contamination of DDT helped give rise to the US EPA, it took the 
medical tragedy of diethylstilbestrol (DES) to highlight the need for thorough screening and 
testing programs to identify compounds that may alter normal hormone regulated processes. 
 DES is a nonsteroidal synthetic estrogen that was given to women in the US between 
1940 to 1970 with the intent of preventing miscarriages [113]. However, in the late 1960s, 
several young women between the ages of 15-22, who were seen at the Massachusetts General 
Hospital, were found to have clear cell adenocarcinoma of the vagina which was previously not 
observed in patients under the age of 30 [116, 117]. It was later determined that the mothers of 
these young women had previously all received DES during the first trimester of pregnancy. 
Gestational exposure to DES is associated with a range of health issues in both sons and 
daughters of women exposed to DES [113]. Among the daughters, infertility and reproductive 
tract abnormalities, such as a T-shaped uterus, were associated with maternal DES exposure 
[118, 119]. Among the sons, DES exposure was associated with an increased likelihood for the 
formation of non-cancerous epididymal cysts with some inconsistent findings as whether DES 
exposure was associated with infertility and genital abnormalities (cryptorchidism and 
hypospadias) [120-122]. The medical problems associated with DES exposure is just one 
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example that led to an increase in environmental research and awareness concerning the potential 
effect of hormone mimics on human health [123]. 
In 1996, the US Congress issued a legislative mandate to the US EPA to establish an 
endocrine screening and testing program which culminated in the formation of the Endocrine 
Disruptor Screening and Testing Advisory Committee (EDSTAC) [113]. In that same year, the 
US EPA provided the following definition of an “endocrine disruptor” [124]:   
“An endocrine disruptor is an exogenous agent that interferes with the production, 
release, transport, metabolism, binding, action, or elimination of natural hormones 
in the body responsible for the maintenance of homeostasis and the regulation of 
developmental processes” (Kavlock, 1996).  
Similar definitions of an endocrine disruptor were later put forth by EDSTAC [125], the 
European Union [126], and the World Health Organization [127]. A more recent definition of an 
endocrine disruptor was proposed by the Society of Endocrinology as “an exogenous chemical, 
or mixture of chemicals, that interferes with any aspect of hormone action” [125]. Today, the 
field of endocrine disruption has significantly expanded to investigate compounds such as 
phthalates [128], DDT and its analogs [129], methoxychlor [130], ultraviolet filters (UV-filters) 
[131], bisphenols [132, 133], and parabens [134] for their potential adverse effects on hormone 
regulated processes in humans and animals. Although many of these compounds have been 
determined to have binding affinities several order of magnitude weaker than endogenous 
hormones such as estrogens and androgens, it is the ubiquitous and chronic exposure to 





Phthalates are plasticizer compounds that are commonly used in polyvinyl chloride and medical 
tubing as well in numerous consumer products such as cosmetics, paints, and lubricants [128]. 
Previous studies have indicated that phthalates display evidence of anti-androgenic behavior with 
weak estrogen effects [135]. For example, di-n-butyl phthalate (DBP) does not induce an 
increase in uterine weight or uterotrophic response in ovariectomized female rats exposed to this 
compound [135]. Furthermore, DBP, di-(2-ethylhexyl) phthalate (DEHP), and their metabolites 
do not appear to compete for or bind to AR in transcriptional activation assays [136, 137]. 
However, numerous studies have provided evidence suggesting that phthalates primarily behave 
as environmental antiandrogens [136, 138]. Prenatal exposure to DBP, DEHP, benzyl butyl 
phthalate (BBP), and di-isononyl phthalate (DINP) have been shown to induce testicular 
abnormalities and other reproductive malformation in androgen-dependent tissues in male rats 
[136, 138]. Similarly, male rabbits exposed to DBP at a dose of 400 mg/kg/day in utero 
(gestation days 15 – 29) had a reduction in numbers of ejaculated sperm, testis weight, and 
accessory sex gland weight relative to control animals [139]. A recent report detected the 
presence of two metabolites of diisopentyl phthalate (DiPeP), one of the most potent anti-
androgenic phthalates, in 98% of all early pregnancy (<16 weeks) urine samples from women in 
Brazil [140]. It has been shown that DiPeP is more potent than DBP for inhibiting fetal 
testosterone production among pregnant rats exposed to either of these compounds (gestation 
days 14 – 18) [140]. Further research is needed to assess the potential risk from exposure to 
DiPeP, and similar phthalates, on male reproductive development. 
 
DDT and its Analogs 
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DDT and it analogs are organochlorine insecticides which were widely used from the 
1940s to late 1970s for insect and malaria control [129]. Today, most countries have banned the 
use of DDT primarily over ecological concerns [129]. Although its common trade name is DDT, 
technical grade DDT typically contains a mixture of several isomers with the largest percentage 
of the mixture being attributed to p,p'-DDT [141]. Some reports have found that chronic 
exposure to DDT has been associated with tumor formation in the liver and adverse reproductive 
effects in wildlife [142, 143].  
In the late 1960s, Derek Ratcliffe reported on an association between the increased use of 
DDT and the observed eggshell thinning contributing to the population decline in several species 
of birds [144, 145]. Experimental evidence has shown that a metabolite of p,p'-DDT, known as 
p,p'-DDE, is responsible for the eggshell thinning effect observed in some species of bids and 
this has been reviewed extensively [146]. Kelce et al. showed that p,p'-DDE is a potent androgen 
receptor antagonist in vitro and this metabolite exhibits antiandrogenic effects in male mice 
[147]. Treating male mice with 100 mg/kg p,p'-DDE led to delayed onset of puberty and a 
reduction in prostate and seminal vesicle weight suggesting that exposure to this metabolite may 
induce abnormalities in male sex development [147]. Technical grade DDT also contains ~15% 
o,p'-DDT, an isomer of p,p'-DDT, which has been shown to act as a potent ERα agonist in 
competitive receptor binding assays [147]. Data showing that o,p'-DDT is an ERα agonist 
suggests that it is a component of technical grade DDT contributing to endocrine disrupting 
effects in observed in fish and wildlife [141, 143]. Due to their lipophilic nature, environmental 
persistence, and the reintroduction of these compounds in some parts of the world for malaria 
control, human exposure to DDT and its analogs remains as a topic of relevance and concern 





Methoxychlor is the p,p'-dimethoxy analog of p,p'-DDT that was originally intended to be a 
replacement for DDT due to its low acute toxicity, short biological half-life, and decreased 
potential for bioaccumulation [148]. Several studies have determined that metabolites of 
methoxychlor are ERα agonists and likely provided a basis for its ban when it was denied 
reregistration by the US EPA in 2004 [148]. Wilson et al. used a luciferase reporter assay to 
show evidence that HPTE, a metabolite of methoxchlor, binds to ERα and promotes estrogen-
dependent gene activation that could be inhibited by co-treating with a potent antiestrogen [149]. 
Further in vivo data has shown that the male pups of female rats exposed to methoxychlor exhibit 
reduced weight of the testis, epididymis, seminal vesicles, and prostate [150]. In female pups, 
methoxychlor treatment lead to a mixture of estrogenic and antiestrogenic effects which included 
accelerated vaginal opening, constant estrus, and atrophy of the uterus and ovaries in normal 
intact females [130, 150, 151]. In contrast, methoxychlor induced an estrogenic effect in 




UV-filters are a class of chemicals that absorb a broad spectrum of UV radiation which is why 
they are widely used in personal care products (PCPs) such as sunscreens, lotions, lipsticks, and 
creams [131, 152]. The lipophilic properties of UV-filter compounds allow to them to be ready 
absorbed across the skin and serves as a major route exposure in humans [131, 153]. Several 
UV-filter compounds have been shown to exhibit weak estrogenic behavior, including 
benzophenone-3 (BP3) which is one of most common UV-filter compounds found in PCPs [154, 
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155]. In vitro studies have shown that UV-filter compounds BP-3, 4-methyl-benzylidene 
camphor (4-MBC), and octyl-methoxycinnamate (OMC) can promote increased cell proliferation 
of estrogen-dependent MCF-7 cells and induce a uterotrophic effect in immature rats [154]. 
Wielogórska et al. characterized BP-3, 4-MBC, and OMC using an ERE-luciferase reporter 
assay and also showed evidence of weak estrogenic behavior for these three UV-filter 
compounds [156]. Interestingly, an epidemiological study reported a possible association 
between a metabolite of BP-3, benzophone-1, and an increased risk of endometriosis in women 
[157]. The potential relationship between UV-filter compounds with estrogen-dependent diseases 
such as endometriosis requires further mechanistic studies to elucidate the possible mechanisms 




Bisphenol-A (BPA) is widely used in the manufacture of polycarbonate plastics used in bottles 
and toys, epoxy resins used in the lining of metal cans, and in numerous other plastic consumer 
products [132, 158]. Several studies have suggested that BPA is a thyroid hormone disrupting 
chemical whereas some in vivo studies suggest that BPA does not affect thyroid hormone levels 
[159, 160]. Aung et al. conducted a case-control study of pregnant women and observed an 
inverse association between urinary BPA levels with thyroid stimulating hormone measured in 
plasma [161]. These findings suggest that exposure to BPA during vulnerable periods of 
gestation may influence fetal development, however, further studies are needed to understand the 
mechanism behind the inhibition of thyroid stimulating hormone and BPA in humans. Additional 
studies have provided evidence that BPA behaves as a weak estrogen and is able to bind to ERα 
[133, 162]. Naciff et al. studied pregnant rats and compared changes in global gene expression 
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profiles from tissues of pups that were exposed in utero to BPA and two other ERα agonists 17 
α-ethynyl estradiol (EE) and the phytoestrogen genistein [163]. They found that all three 
compounds significantly upregulated the same 50 ER-regulated genes which suggests BPA has a 
common mode of action with known ERα agonists such as EE and genistein [163].  
Murray et al. previously studied the relationship between the weak estrogenic behavior of 
BPA and its effect on mammary gland development by exposing rats to 2.5 µg/kg BW/day of 
BPA during gestation [164]. They found that adult rats (postnatal day 95) exposed to BPA during 
gestation were observed with an increase of intraductal hyperplasias in the mammary glands. 
Tissue sections from epithelial cells in the intraductal hyperplasias were determined by 
immunostaining to have significantly higher expression of ERα compared to normal mammary 
glands with additional evidence of increased proliferative activity. They concluded that the 
increased expression of ERα in the hyperplastic tissues suggest that the proliferative activity 
among these cells might be driven by estrogen and that these tissues are more likely to be 
stimulated by estrogens later in life [164]. Murray et al. also speculated that their findings 
support the hypothesis that fetal exposure to BPA and estrogen mimics may contribute to an 
increased risk of breast cancer later in life that might be attributed to altered mammary gland 
morphology. This same group conducted a similar study in nonhuman primates which were 
exposed to BPA during gestation and observed subtle but significant differences in 
morphological parameters in mammary gland density versus unexposed controls [165]. Although 
morphometric analysis indicated that the overall development of the mammary gland tissue was 
more advanced in the BPA treatment groups, immunostaining did not show evidence of 
increased ERα expression as reported in their earlier rodent study. Taken together, these in vivo 
findings are relevant in the context of breast cancer development in humans in light of evidence 
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that high mammographic density is associated with an increased risk of developing breast cancer 
[166].  
The concern over the potential endocrine disrupting effects attributed to BPA has led to a 
reduction in its commercial use and the recent implementation of BPA substitutes bisphenol-S 
(BPS) and bisphenol-F (BPF) in numerous consumer goods [167]. Interestingly, comprehensive 
reviews of the reported literature suggests that both BPS and BPF exhibit similar hormonal 
activity as BPA where they have been found to induce similar in vivo effects such as promoting 
an increase in uterine weight in rats [167]. The widespread exposure of bisphenols and their 
potential endocrine disrupting effect on humans remains as a current issue that warrants further 




Parabens, and their analogs, are alkyl esters of 4-hydroxybenzoic acid that are commonly used as 
preservatives in numerous consumer products including lotions, creams, cosmetics, 
pharmaceuticals, shampoos, sunscreens, and several other types of PCPs [152, 170, 171]. The 
widespread use of parabens in PCPs has led to research studies to determine the extent of human 
exposure and investigate whether there is evidence for endocrine disrupting behavior [131]. In 
vitro studies have shown that parabens exhibit weak estrogenic behavior, bind to ERα to promote 
ER-dependent gene transcription, and induce increased cellular proliferation of ER-dependent 
breast cancer cells [156, 162, 172-174]. Evidence of estrogenic behavior for n-butylparaben in 
vivo was observed when Hu et al. treated immature Sprague Dawley rats at a dose of 0.16 
mg/kg/day for three days via intragastric administration [175]. Hu et al. found that n-
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butylparaben was able to induce an estrogenic response in the immature rats which was assessed 
by an increase of uterine weight [175].  
Although parabens are rapidly metabolized in humans, studies have detected their 
presence in adipose, placental, and breast tissue, as well as breast milk, serum, seminal fluid, and 
urine [134, 176-183]. A common finding among many biomonitoring studies is that urinary 
concentrations of parabens in women tends to be several-fold higher than in samples from men 
[182-185]. Other reports suggest differential exposure among women exposed to parabens and 
related environmental phenols and these appear to be associated with race/ethnicity and 
geographic location [185-187]. In men, n-butylparaben has been associated with markers of 
DNA damage in sperm [178]. Similarly, reduced sperm production in male rats has been shown 
when they are exposed to either propylparaben or n-butylparaben in their diet [188-190]. Despite 
these findings, Nishihama et al. did not detect an association between male urinary paraben 
exposure and semen parameters, however, the study’s small sample size may have limited the 
power to detect a true association [191].   
Among third trimester pregnant women, higher concentrations of parabens measured in 
maternal urine and cord blood were associated with an increased risk of pre-term birth, reduced 
birth weight, and decreased birth length [192]. Nishihama et al. provided evidence that parabens 
exhibit endocrine disrupting behavior when they reported a dose dependent association between 
paraben exposure and shorter self-reported menstrual cycle lengths among female Japanese 
university students [170]. Interestingly, Pollock et al. treated female mice with 3 mg of n-
butylparaben by subcutaneous injection and found that urinary E2 concentrations were elevated 
in the mice 6 hours after the initial treatment [193]. These in vivo findings support the human 
data presented by Nishihama et al. which suggests that parabens may influence normal 
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reproductive function. Moreover, these data suggest paraben exposure may have additional 
implications in estrogen-dependent diseases such as breast cancer. For example, breast tissue 
concentrations of iso-butylparaben and n-butylparaben measured in patients with 
ER+ progesterone receptor (PR)+ primary breast tumors have been detected at relevant effect 
concentrations determined in in vitro studies [176]. For example, iso-butylparaben and n-
butylparaben were measured in breast tissue samples at concentrations near their experimentally 
determined half maximal effective concentration (EC50) or EC30 respectively [174]. However, 
control breast tissue samples from healthy women were not included in this study which makes it 
difficult to determine if weakly estrogenic compounds like parabens have a role in breast cancer 
or not. The ubiquitous human and wildlife [194, 195] exposure to estrogenic paraben compounds 
and their associations with potentially altering estrogen regulated processes warrants further 
investigation.  
As will be discussed in greater detail in the following sections, most diagnosed breast 
tumors express ER and cellular proliferation can be induced by endogenous estrogens. EDCs that 
exhibit estrogenic behavior, including some of the compounds described above, are suspected to 
play role in ER-dependent tumor progression. Alternatively, EDCs may also contribute to breast 
cancer recurrence and contralateral breast cancer in a subset of women receiving adjuvant 
endocrine therapy. A discussion on the prominent relationship between estrogen and ER pathway 
in breast cancer follows.      
 
The Role of Estrogen and the ER Pathway in Breast Cancer 
 
Breast cancer is currently the most commonly diagnosed malignancy among women in the 
United States (US) with an estimated 266,000 new diagnoses and 41,000 deaths in 2018 alone 
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[196]. Despite these numbers, the mortality rate for breast cancer has been steadily declining 
over the last three decades [196]. The reported decline in the mortality rate has largely been 
attributed to early detection, significant advancements in patient treatment, and a greater 
understanding of the biological mechanisms driving different breast tumor types [197].  
 
Tumor Cell Subtypes in Breast Cancer 
 
There are at least four different molecular subtypes in breast cancer which are characterized by 
the expression of biological markers that include ER, PR, and the receptor tyrosine-protein 
kinase epidermal growth factor receptor 2 (HER2) [198, 199]. Luminal A, or hormone-receptor 
positive (HR+/HER2-) breast cancer, accounts for approximately 70% of all diagnosed breast 
tumors and are more likely to produce a favorable response to endocrine therapy [14]. The 
Luminal A tumor subtype is characteristically identified by the prominent expression of ER 
and/or PR but not HER2 with a tendency to be less aggressive than the other breast cancer 
subtypes. The Luminal B, another HR+ subtype, comprises 10% of diagnosed tumors and is 
identified by the expression of ER and/or PR as well as HER2 expression. In contrast, triple 
negative breast cancer does not express ER, PR, or HER2 and accounts for approximately 12% 
of breast cancer diagnoses. Triple negative breast cancer is generally more aggressive than the 
other subtypes and is twice as common in African American women compared to Caucasian 
women in the US [200]. Patients with triple negative breast cancer also tend to have poorer 
prognosis’ due to the lack of targeted therapies for this subtype. The last major molecular 
subtype is referred to as HER2-enriched (HR-/HER2+) and makes up 20% of all breast cancer 
diagnoses. Although the HR-/HER2+ subtype may spread more aggressively than HR+/HER2- 
breast cancer, developments in targeted therapy for HR-/HER2+ has led to improvements in 
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reported patient outcomes for this molecular subtype [201]. Since HR+/HER2- breast cancer 
accounts for most breast cancer diagnoses, the following sections will provide a historical 
account on discovering the relationship between estrogen and breast cancer as well as a brief 
commentary on the critical issue of breast tumor recurrence. 
 
Discovering the Relationship Between Breast Cancer and Estrogen 
 
The first documentation that endogenous ovarian hormones may be associated with breast cancer 
was noted by a surgeon at Middlesex Hospital by the name of Thomas William Nunn [202]. In 
1882, Nunn recorded the case history of a perimenopausal woman with breast cancer, whose 
disease regressed 6 months after her menstruation ceased [202]. Although Nunn’s observations 
were an important first step in connecting ovarian function and its production of estrogen with 
breast cancer, his findings largely went unnoticed at the time. Later in 1889, Albert Schinzinger 
proposed oophorectomy, the surgical removal of the ovaries, as a treatment for breast cancer but 
it appears that he was not able to fully convince his colleagues to use this procedure [203]. Soon 
after in 1896, a British physician named Sir George Thomas Beatson described a bilateral 
oophorectomy that he performed on a patient with metastatic breast cancer who showed signs of 
improvement and remission of her tumor for at least eight months after the operation [204]. In 
1900, Stanly Boyd would later report that 35% of breast cancer patients who received an 
oophorectomy would exhibit some form of benefit and their tumors temporarily regressed after 
the procedure [205]. Although Beatson would be recognized for establishing oophorectomy as a 
treatment for breast cancer, a full understanding of the biological mechanism by which the 
procedure works in a subset of patients would not emerge until many years later.  
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 In 1960, Jensen and Jacobson showed that radiolabeled E2 injected into immature female 
rats would localize and be retained in specific target tissues that included the uterus and vagina 
but not in others such as the kidneys or liver [206]. This fundamental discovery led to subsequent 
reports describing the biochemical response and nuclear localization of an estrogen receptor that 
was bound to radiolabeled E2 in cell extracts from rat uterus [207]. A later study also used 
radiolabeled E2 and determined that the antiuterotropic effect of ethamoxytriphetol, the first non-
steroidal antiestrogen, mechanistically worked by preventing binding and localization of E2 in 
rat uterus [208]. The discovery of the biological mechanism behind ethamoxytriphetol’s 
antiestrogenic behavior was influential in providing insight as to why endocrine therapy would 
show clinical benefit in some patients and not others. In 1974, potential benefit of antiestrogens 
were illuminated when the National Cancer Institute sponsored an international workshop that 
examined data from 436 clinical trials to evaluate whether ER expression could be used as a 
prognostic marker to predict response to endocrine therapy [209]. The findings from the 
international workshop were reported in 1975 where it was determined that 55 – 60% of ER 
expressing tumors responded to endocrine therapy while ER-negative tumors showed little to no 
tumor regression following treatment. That same year, Lippman et al. used the ER-positive, E2-
dependent MCF-7 breast cancer cell line to show that the antiestrogen tamoxifen could inhibit 
MCF-7 cell proliferation and E2-induced DNA synthesis and that these inhibitory effects could 
be reversed in the presence of E2 [210, 211]. These early clinical and mechanistic studies in the 
1960s to late 1970s significantly increased our understanding of the importance of estrogen and 




Types of Antiestrogens 
 
Although antiestrogens including tamoxifen have been used clinically to treat both pre- and 
postmenopausal patients with breast cancer, a monohydroxylated metabolite of tamoxifen has 
been found to be a more potent antiestrogen than its parent compound [212]. Mechanistically, 
tamoxifen and its metabolite work by inhibiting agonist binding and prevent ER from adopting a 
stable and active conformation [88]. The instability of ERα is a direct result of a redirection in 
the positioning of Helix 12 which interrupts the recruitment of key coactivator proteins. 
Alternatively, potent pure antiestrogens such as Fulvestrant have been developed that not only 
compete for the active site of ER, but they also induce degradation of the receptor via the 
ubiquitin proteasomal pathway in cytosol [213, 214]. Despite Fulvestrant’s clinical use to treat 
patients with advanced breast cancer [215], this compound’s effectiveness is inherently limited 
to due to its poor bioavailability [213] and must be administered by intramuscular injection. In 
contrast, aromatase inhibitors (AIs) do not compete with E2 for binding to ER and are designed 
to inhibit the enzymatic conversion of androgens to estrogens in the peripheral tissues of 
postmenopausal women [216]. Although the long-term use of third-generation AIs to treat 
postmenopausal women with breast has been shown to be more effective than tamoxifen [217], 
recurrence is common and attributed to de novo and acquired resistance to AIs [174, 218, 219]. It 
has been suggested that exposure to estrogen mimicking compounds, as well as the emergence of 
LBD mutations in advanced breast cancer [220, 221], may explain why a significant number of 
patients will recur after and while receiving endocrine therapy [222]. 
 
Endocrine Therapy Resistance and Recurrence in Breast Cancer 
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Although ERα-P-Ser118 is an example of a prognostic marker that has been reported to predict 
which breast cancer patients might benefit from endocrine therapy at diagnosis [223], additional 
biological markers are needed to identify which patients are more likely to experience a 
recurrence of their cancer. For instance, Pan et al. showed that there is a persistent risk of 
recurrence and death from breast cancer for at least 20 years after receiving 5 years of adjuvant 
endocrine therapy [222]. This persistent risk of breast recurrence was determined to increase at a 
rate of approximately 1 – 2% every year [217] irrespective of a patient’s nodal status and stage 
[222]. For breast cancer patients on AIs, it has been suggested that non-classical estrogens 
arising from androgen metabolism [218], might explain why upwards of 20% of these patients 
will recur within 10 years of receiving endocrine therapy [217, 222].  
Mechanistically, AIs do not prevent the binding of estrogens to ER and instead work by 
minimizing their biological synthesis. Therefore, low concentrations of residual circulating 
estrogens and/or exposure to environmental estrogenic EDCs may offer another potential 
explanation as to why endocrine therapy fails in some breast cancer patients. For instance, 
López-Carrillo et al. conducted a case-control study among women living in the northern states 
of Mexico and showed that exposure to diethyl phthalate was associated with an increased risk of 
breast cancer [224]. Likewise, Cohn et al. conducted as prospective nested case-control study in 
Alameda County, California, and showed that maternal exposure to the potent ERα agonist, o,p'-
DDT, was associated with a increased risk of breast cancer among the daughters of the exposed 
women [225]. Palmer et al. conducted a follow-up cohort study and reported that prenatal 
exposure to DES, a potent nonsteroidal ERα agonist, was associated with an increased risk of 
breast cancer among women greater than 40 years of age [226]. Additionally, adipose tissue 
concentrations of polychlorinated biphenyls (PCBs) from nonmetastatic breast cancer patients in 
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New York were shown to be associated with an increased risk of disease recurrence [227]. 
Another study conducted a meta-analysis of 16 studies and reported a pooled odds ratio that 
indicated a greater risk of breast cancer from several different PCBs [228]. Despite the detection 
of numerous congeners of PCBs in breast tissue, human exposure to these compounds are not 
always associated with clinical and pathological characteristics in breast cancer [229]. Currently, 
there are a lack of studies demonstrating that paraben exposure is associated with an increased 
risk of breast cancer despite their detection in breast tissue [176, 177] at biologically relevant 
concentrations [174]. Future studies are needed to clarify whether parabens, or unidentified 
environmental estrogen mimics, have a role in breast cancer progression or disease recurrence.  
Although some EDCs have been associated with an increased risk of breast cancer, 
another explanation for why patients recur while on endocrine therapy is due to presence of LBD 
domain mutations discovered in ERα [221, 230, 231]. Interestingly, these LBD mutations are 
rare in primary breast cancer tissue and have been reported to be present at very low mutant 
allele frequencies [232]. However, emerging evidence suggests that these mutations evolve 
under the selective pressure of aromatase inhibitor therapy and likely are a mechanism of 
acquired resistance to AIs [233-235]. Two of the most common LBD mutations are found in 
Helix 12 of ERα, Y537S and D538G, and are frequently detected in 30 – 40% of ER-positive 
metastatic breast cancer patients. Chandarlapaty et al. evaluated the relationship between the 
presence of LBD mutations and clinical outcomes using baseline plasma samples from 541 
postmenopausal women with metastatic breast cancer enrolled in the BOLERO-2 double-blind 
phase 3 study [236]. They analyzed cell-free DNA from the baseline plasma samples and showed 
that the Y537S and D538G mutations were associated with worse clinical outcomes including 
shorter median overall survival. In vitro data has indicated that the LBD mutations appear to 
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confer ligand-independent receptor activation of ERα and promote constitutive activity of ER 
mediated cell proliferation [220, 221]. Furthermore, in vitro studies have indicated that some 
antiestrogens used to treat breast cancer, (ie: tamoxifen and Fulvestrant), are less potent in cell 
models expressing these ERα LBD mutations [220, 221, 230]. In summary, these studies 
highlight critical need to develop more potent and selective antiestrogens to effectively treat 
breast cancer patients who may be harboring ERα LBD mutations in their tumors. 
  
Rationale for Thesis  
 
Although endocrine therapy for ER-positive breast cancer has been shown to be effective, 
disease recurrence is a prominent and unresolved issue. The characterization of recently 
identified metabolites of paraben compounds used in numerous consumer goods will be 
explored. The data presented in Chapter II suggest that the oxidized paraben metabolites 
represent an equally important component of paraben exposure. Therefore, these metabolites 
should be accounted for in studies seeking to determine an association between parabens and 
endocrine disruption or breast cancer progression. Novel approaches to identify environmental 
estrogens and those that may be used in manufacturing of consumer items are currently lacking. 
In Chapter III, I will demonstrate the utility of using an in silico approach to identify ERα 
agonists and show how this methodology can be applied in the development of potentially safer 
and less estrogenic paraben compounds that could be used in the manufacture of consumer 
products. Regardless of whether exposure to estrogenic EDCs are conclusively determined to 
have a role in breast cancer or not, more potent and orally bioavailable antiestrogens are 
currently needed to effectively treat ER-positive breast cancer. In Chapter IV I will present in 
vitro data on the characterization and development of novel degraders of ERα for applications in 
targeted therapy for ER-positive metastatic breast cancer patients.  
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Figure 1.1. Gonadal Steroidogenesis. Depiction of major biosynthetic pathways in the gonads. 









Figure 1.2. Schematic representation of Estrogen receptor domains. The structural domains 
comprising full length ERα (ERα66), its isoforms (ERα46 and ERα36), and ERβ. The ER 
domains include activation function-1 domain (AF-1), the DNA-binding domain (DBD), the 
hinge domain, and the ligand-binding domain/activation function-2 domain (LBD/AF-2), F-
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Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in 
MCF-7 and T47D Human Breast Cancer Cell Lines 
Introduction 
 
Breast cancer is currently the most commonly diagnosed malignancy among women in 
the United States (US) with an estimated 266,000 new diagnoses and 41,000 deaths in 2018 
alone [1]. An estimated 7% of breast cancer diagnoses are attributed to an inherited genetic 
predisposition with the remaining ~93% being attributed to other likely risk factors such as 
lifestyle choices, obesity, or exposure to environmental carcinogens [2]. In addition, lifetime 
exposure to estrogens has been shown to be correlated with breast cancer risk [3]. Both 
preclinical and clinical studies have shown that estrogens, specifically 17ß-estradiol (E2), can 
induce breast cancer pathogenesis [4, 5]. The ability of estrogen to induce breast cancer cellular 
proliferation is concerning because it is estimated that approximately 70% of all diagnosed breast 
cancers express the estrogen receptor (ER) and are deemed ER-positive [6]. Pharmacological 
approaches have been developed to block ER signaling using ER antagonists such as tamoxifen, 
and more recently aromatase inhibitors (AIs), which inhibit the synthesis of estrogens [7], have 
been used. While highly effective, de novo and acquired resistance to AIs is common, and a 
possible mechanism of resistance is attributed to exposure to environmental estrogen mimicking 
chemicals, or xenoestrogens [8, 9] including the ones we chose to study in this report [10]. 
Recently, there has been increasing public awareness and research into environmental 
chemicals that may have biologically relevant, endocrine disrupting properties [11]. 
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Xenoestrogens include many of these suspected endocrine disrupting compounds that have 
previously been shown to display agonistic behavior toward estrogen receptor-α (ERα) [12, 13]. 
Alkyl esters of p-hydroxybenzoic acid (parabens) are one type of xenoestrogen that have been 
investigated for whether current human exposure levels are a cause for concern [14]. Given their 
antimicrobial properties, parabens are frequently used as a preservative in numerous 
pharmaceuticals, food products, and personal care products [15, 16]. Compared to oral ingestion, 
dermal contact encompasses a broader range of paraben exposure sources that are found in 
numerous cosmetics and personal care products [17]. As an example, daily paraben exposure for 
a 63 kg average adult in Korea is estimated to be a sum total of 18,960 µg/day for methyl and 
ethylparaben combined, and 1,580 µg/day for propyl paraben alone [18]. Similarly, dermal 
intake of parabens has been estimated to be 31 µg/kg-bw/day for adult females and range 
between 58.6 to 766 µg/kg-bw/day among infants and toddlers within United States in 2012 [15]. 
Exposure estimates for parabens in Belgium, Germany, and several other nations have been 
summarized and reported elsewhere [19-22]. The ubiquitous exposure to parabens has led to 
reports of their detection in breast tissue, breast milk, placental tissue, serum, seminal fluid, and 
urine samples from numerous general populations around the world [19, 23-27]. In spite of 
evidence showing the presence of parabens in various human tissues such as adipose [28] and 
breast tissue [29], there is still significant debate over their current risk to the general population. 
To date, studies have focused on the estrogenic properties of paraben parent compounds 
[12, 30-32]. Two oxidized paraben metabolites, 3-hydroxy n-butyl 4-hydroxybenzoate (3OH) 
and 2-hydroxy iso-butyl 4-hydroxybenzoate (2OH) (Figure 2.1), have recently been discovered, 
but their potential estrogenic properties have not yet been studied [10]. Unlike E2, which forms 
three hydrogen bonds in the ligand binding pocket of human ER according to X-ray 
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crystallography structures [33], BuP is unable to hydrogen bond with His524 [11]. The lack of a 
second hydroxyl group on BuP likely contributes to its relatively weak ER binding affinity. We 
hypothesized that the metabolites’ additional hydroxyl group might enable binding interactions 
similar to that of 17ß-estradiol and confer increased estrogenic potency compared to their 
respective parent compounds. To test this, we used pre-clinical in vitro models of ER-positive 
breast cancer and demonstrated that the oxidized metabolites promote cell proliferation in an ER-
dependent manner comparable to their respective parent compounds. Computational docking 
studies indicated that the metabolites display hydrogen bonding capabilities similar to 17ß-
estradiol within the human ERα ligand-binding domain in support of our in vitro data.  
 
Materials and Methods 
 
Reagents  
17ß-estradiol (E2), ICI 182,780 (ICI), and n-butylparaben (BuP) were purchased from Sigma-
Aldrich Inc. (St. Louis, MO) with purity ≥ 98% determined by HPLC. 5α-Androstan-17β-ol-3-
one (DHT) was purchased from Sigma-Aldrich Inc. (St. Louis, MO) with purity ≥ 97 % 
determined by TLC. E2, DHT, and ICI were dissolved to 10 mM in absolute ethanol and stored 
at -20 °C.  Iso-butylparaben (IsoBuP) was purchased from TCI America (Portland, OR) with 
purity ≥ 98% determined by HPLC. 3-hydroxy n-butyl 4-hydroxybenzoate (3OH) and 2-hydroxy 
iso-butyl 4-hydroxybenzoate (2OH) were kindly provided as a gift by Dr. Vladimir Belov, Max 
Planck Institute for Biophysical Chemistry in Germany. The 3OH and 2OH compounds had a 
purity ≥ 95 % determined by HPLC with UV (254 nm) detection. BuP, IsoBuP, 3OH, and 2OH 
were dissolved to 100 mM in DMSO stored at -20 °C. The final concentration of ethanol or 




Cell lines, culture conditions, and proliferation assays   
MCF-7, T47D, and MDA-MB-231 cells were obtained from the Tissue Culture Shared Resource 
(TCSR) at the Lombardi Comprehensive Cancer Center (Georgetown University, Washington, 
DC). LNCaP cells were obtained from the laboratory of Ken Pienta at the University of 
Michigan. Cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco/Life 
Technologies, Grand Island, NY) supplemented with 10 % (v/v) fetal calf serum (Valley 
Biomedical Inc., Winchester, VA), at 37 °C in a humidified 5 % (v/v) CO2 atmosphere. The 
identity of the cells was confirmed by short tandem repeat profiling by the TCSR and shown to 
be free of mycoplasma contamination. For assays in defined steroid deplete conditions, cells 
were repeatedly washed and grown in steroid depleted media over 3 days before proliferation 
assays (phenol red-free IMEM supplemented with 10 % (v/v) charcoal stripped bovine calf 
serum – CCS) (Valley Biomedical Inc., Winchester, VA) based on a previously described 
method [34]. For growth assays, MCF-7, T47D, MDA-MB-231, and LNCaP cells were 
withdrawn from steroids as previously described [35] and plated in steroid-free media at 1000 
cells / well, 2000 cells / well, 500 cells / well, and 7000 cells / well respectively in 96-well plates 
and allowed to attach overnight. LNCaP cells were plated in 96-well plates coated with poly-D-
lysine to improve cell adhesion. LNCaP cells were treated with indicated compound within 1 hr 
of plating. 
 
PrestoBlue® cell viability assay 
MCF-7 and T47D cells were plated in steroid-free media at 1000 cells / well and 2000 cells / 
well, respectively, in 96-well plates and cultured overnight. The following day, cells were treated 
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with the specified compounds at the indicated concentrations and the vehicle controls (ethanol or 
DMSO) diluted in IMEM supplemented with 10 % (v/v) CCS. Six days after treatment, cell 
viability was assessed using Presto Blue reagent (ThermoFisher Scientific, Waltham, MA) 
according to manufacturer’s instructions. Briefly, cells were incubated for 3 hrs in the presence 
of 10 % (v/v) Presto Blue and fluorescence was measured using a POLARstar Omega plate 
reader with the excitation/emission wavelengths set at 544/590 nm. Cell viability data was 
confirmed using the crystal violet assay based on a previously described method [36].  
 
RNA Expression Assay 
MCF-7 cells were repeatedly washed and grown in steroid depleted media over 3 days as 
described above and plated in steroid depleted media at 400,000 cells/well in 6-well 
plates at least 10 hours before treatment with parabens for 2, 4, and 6 hour durations. Total RNA 
was isolated using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA) according to the 
manufacturer’s instructions. Yield and quantity were determined by spectrophotometry 
(NanoDrop ND-1000). All samples were stored at -80 °C. Total RNA (1 µg) was reverse 
transcribed (RT) using Reverse Transcription System (Promega, Madison, WI) and the cDNA 
amplified in a 25 µl reaction containing Gene Expression Master Mix and gene specific primers 
both from Thermo Fisher Scientific (Waltham, MA). GREB1 mRNA expression was measured 
using a TaqMan RT-PCR assay as described previously [34]. GREB1 expression was normalized 
against GAPDH with relative expression being calculated using the ΔΔCT method [37]. 
 
Estrogen-response element (ERE)-luciferase reporter assay  
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The ERE-luciferase reporter plasmid (a gift from Dr. Anna T. Riegel, Georgetown University) 
was co-transfected into MCF-7 cells with Fugene 6 transfection reagent (Promega, Madison, WI) 
according to manufacturer’s instructions with the renilla plasmid (100:1 v:v luciferase to renilla). 
After 18 hrs, transfected cells were repeatedly washed with phenol red-free 10 % (v/v) CCS I-
MEM (Valley Biomedical Inc., Winchester, VA) to produce a steroid-free environment. The 
following day cells were plated in a 24-well plate (Corning/Costar) in 10 % (v/v) CCS I-MEM 
(Valley Biomedical Inc., Winchester, VA). After 6 hrs, cells were treated with either 2OH, 3OH, 
BuP, IsoBuP, E2, or a vehicle control (ethanol or DMSO). After 18 hrs, cell lysates were 
processed and relative light unit (RLU) reading were measured according to manufacturer’s 
recommendations on a Leader 50 luminometer (Gen-Probe).   
 
Molecular Docking  
The crystal structure of the human ERα ligand-binding domain in complex with 17ß-estradiol 
was downloaded from the protein data bank PDB ID: 3UUD and  prepared for docking with the 
YASARA molecular modelling suite [38]. The PDB entry 3UUD was selected for docking due 
to its high resolution (1.6 Å). The presence of an endogenous ligand was another factor 
considered when selecting this structure to ensure that the ligand binding domain was a suitable 
representation of the agonist conformation. All crystallographic waters were removed, hydrogen 
atoms were added, bond orders were corrected for S-hydroxycysteine residues, missing loops 
were repaired [39], and only the A-chain was retained. Docking was performed with VINA [40] 
using default parameters, and setup was conducted with YASARA as the graphical front-end 
[41]. A grid size of 25 Å × 25 Å × 25 Å was centered on the C9 carbon of E2 before removing 
the native ligand and set as the search space for the paraben compounds treated as flexible 
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ligands. The best pose of 25 runs was defined as producing the smallest root-mean-square 
deviation (RMSD) between the benzoyl group of the paraben compounds and comparable carbon 
atoms (1-5, 9, & 10) and phenol oxygen atom of the phenolic-A ring of E2. Hydrogen bond 
networks of the docked structures were optimized with YASARA before determining RMSD 
values [42]. 
 
2D Interaction Diagrams 
The 2D ligand interaction diagrams were drawn using BIOVIA Discovery Studio Visualizer [43] 
 
Statistical Analysis 
The curve-fitting program GraphPad Prism 7.0 was used to plot all data. The time and relative 
fold expression of GREB1 within each treatment group was processed by one-way ANOVA (P < 
0.005) followed by a Bonferroni post hoc analysis to determine which time points differed from 
each other. Technical replicates were derived and analyzed from the same sample source across 
the indicated treatment conditions. Each set of technical replicates were independently validated 




3OH and 2OH butyl paraben metabolites induce the proliferation of estrogen-dependent 
human breast cancer cells grown in steroid-free conditions 
To determine the whether the paraben metabolites could induce human breast cancer growth, 
estrogen-dependent MCF-7 and T47D cell lines were treated with BuP, IsoBuP, and their 
respective metabolites. The calculated effective concentrations inducing 50% growth (EC50) for 
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BuP and IsoBuP (1.2 µM & 0.30 µM respectively) were similar to those reported previously [11, 
29, 44, 45] (Figures 2.2A – 2.2D). MCF-7 cells treated with the 3OH (Figure 2.3A) and 2OH 
(Figure 2.3B) paraben metabolites induced cellular proliferation in a concentration-dependent 
manner. T47D cells treated with 3OH (Figure 2.3C) or 2OH (Figure 2.3D) required slightly 
higher concentrations than MCF-7 cells to induce proliferation but they did not achieve a 
sigmoidal concentration dependence. Higher concentrations of the 3OH metabolite would exceed 
0.1% DMSO vehicle concentration which prevented an EC50 from being determined in the T47D 
cell line. The EC50 for 3OH and 2OH in MCF-7 and T47D cells was calculated (3OH: EC50 8.0 
𝜇M in MCF-7; 2OH: EC50 2.2 𝜇M in MCF-7 and 43.0 𝜇M in T47D). All PrestoBlue® cell 
viability assay results were confirmed with the crystal violet growth assay as described in 
Materials and Methods (data not shown). Previous reports have investigated the androgenic and 
anti-androgenic behavior of parabens [46, 47] prior to the discovery of the 3OH and 2OH 
paraben metabolites. Therefore, we also examined whether the 3OH and 2OH paraben 
metabolites exhibited androgenic properties by treating androgen-dependent LNCaP cells and we 
found that the paraben metabolites do not exhibit androgenic behavior at concentration ranges of 
10 pM – 10 𝜇M (Figure 2.4A and 2.4B). Non-estrogen receptor α expressing MDA-MB-231 
cells were treated with 3OH, 2OH, and their respective parent compounds to show no effect on 
cell proliferation. (Figure 2.5A – 2.5D). 
 
The pure anti-estrogen receptor antagonist (ICI 182,780) inhibits 3OH and 2OH metabolite 
induced proliferation of estrogen-dependent human breast cancer  
To confirm that the cell proliferation induced by 3OH and 2OH paraben metabolites was due to 
ERα signaling, we assessed whether their proliferative effects could be blocked by the pure anti-
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estrogen ICI 182,780 (Fulvestrant). Estrogen-dependent MCF-7 cells were treated at the 
identified EC50 concentrations of BuP (1.2 µM), IsoBuP (0.3 µM), and their metabolites either 
alone or in the presence of increasing concentrations of ICI. BuP and IsoBuP induced 
proliferation was inhibited by ICI at 0.8 nM and 1.4 nM, respectively, comparable to previous 
reports [32] (Figure 2.6A and 2.6B). Cell proliferation induced by the 3OH and 2OH paraben 
metabolites was inhibited in a concentration-dependent manner by ICI with an IC50 of 0.7 nM 
and 1.2 nM respectively (Figure 2.6A, and 2.6B).  
 
3OH and 2OH metabolites induce expression of the estrogen regulated gene, GREB1 
To confirm the estrogen agonist action of the paraben metabolites we tested the ability of these 
compounds to induce the expression of an estrogen responsive gene, GREB1. We measured the 
effects of paraben-treated ER-positive MCF-7 cell lines on GREB1 mRNA levels. GREB1 is a 
critical downstream target of ERα signaling the expression of which is induced by exposure to 
E2, which can be suppressed by ICI 182,780 as previously described [34]. GREB1 has also been 
described as a critical estrogen-specific ER-interacting protein, an interaction that has been 
shown to be highly enriched upon estrogen exposure [48]. ER-positive MCF-7 cells were treated 
at 10 µM with BuP, IsoBuP, 3OH and 2OH as described in Materials and Methods. E2 was used 
as a positive control; it induced GREB1 expression (~29-fold at 6 hrs; P < 0.001) at all time-
points compared with the vehicle control (Figure 2.7). Treatment with BuP, IsoBuP, 2OH, and 
3OH induced GREB1 expression ~30, ~36, ~20, and ~10-fold at 6 hrs respectively (P < 0.001) 
compared to vehicle control. Neither ethanol nor DMSO significantly affected expression levels 
compared to media (CCS) alone (data not shown). Co-treatment with the paraben compounds 
and the pure anti-estrogen ICI 182,780 at 6 hrs blocked these effects (Figure 2.8).   
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2OH metabolite induces luciferase expression in MCF-7 cells transfected with an estrogen-
responsive luciferase reporter construct  
To further confirm that the estrogenic activity of the paraben metabolites is mediated by classical 
ER mediated signaling, we tested the ability of the compounds to induce ER-dependent 
transcription using an ERE-luciferase reporter construct [49]. The 2OH metabolite significantly 
(P < 0.05) induced transcriptional activity of the ERE-luciferase reporter construct at 10 and 20 
µM (Figure 2.9). Transcriptional activity by the 3OH metabolite was found to be non-significant 
at 10 and 20 µM. BuP and IsoBuP demonstrated increased ERE transcriptional activity 
consistent with previous reports [12, 50] (Data not shown). 
 
3OH and 2OH metabolites can be docked within the ligand binding pocket of estrogen 
receptor α  
To provide additional support that the hydroxylated metabolites were promoting ERE mediated 
transcription and stimulated cellular proliferation, molecular docking was used to characterize 
the interactions of the metabolites as flexible ligands within the known active conformation of 
the ligand binding site of human ERα. The E2 ligand in the crystal structure of ERα (PDB ID: 
3UUD) was removed and re-docked into the active site. The RMSD among all carbon and 
oxygen atoms for the binding pose of the docked E2 ligand and the pose identified in the crystal 
structure of ERα was 0.819 Å, indicating that our prepared ERα structure could accurately 
reproduce experimentally determined binding poses. The high resolution of the 3UUD ERα 
structure (1.6 Å), compared to PDB entries 4TV1 (1.85 Å) and 4MG9 (2.0 Å) ERα structures 
complexed with either propyl- or n-butylparaben respectively, was a significant contributing 
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factor in choosing this structure for docking the hydroxylated paraben metabolites. Docking of 
either propyl- and or n-butylparaben to 4TV1 and 4MG9 resulted in relatively poorer RMSD 
values compared to 3UUD which was another consideration for proceeding with the 3UUD 
structure for this study. The binding poses of the hydroxylated paraben metabolites and their 
respective parent compound were analyzed, and each of them displayed a preference to dock to 
the reported active site of ERα [11].  
Hydrogen bonding interactions of the paraben compounds with key side-chain residues in 
the active site of ERα are shown in Figure 2.10A-2.10C and Figures 2.11A-2.11C. The 2OH 
compound displayed hydrogen bonding capabilities with amino acid residues Arg394 and 
Glu353 (Figure 2.10A) which have been shown to hydrogen bond to the phenol ring of E2 [13, 
33]. 2D interaction diagrams generated with Discovery Studio Visualizer indicated the potential 
for two additional hydrogen bonds to be formed with L387 and G521 (Figure 2.11A). The 
calculated RMSD for E2 and the 2OH metabolite was determined as described in the Materials 
and Methods and indicated a high degree of binding similarity with E2 (0.658 Å). Due to the 
presence of a chiral center located at the secondary alcohol group of the 3OH compound and 
unknown proportions of a potential racemic mixture of our 3OH test substance, it was necessary 
to dock both the R and S isomer of the 3OH compound. The identified binding poses of the R & 
S isomers both suggested favorable hydrogen bonding interactions with amino acids Arg394 and 
Glu353, but the S isomer was additionally capable of forming hydrogen bonds with His524 and 
Gly521 (Figure 2.10B, 2.10C). 2D interaction diagrams showed that the R & S isomer may both 
form additional hydrogen bonds with L387 but only the S isomer may form an additional 
hydrogen bond with L525 (Figure 2.11B, 2.11C). The calculated RMSD for E2 compared with 
the 3OH R & S isomers both indicated a high degree of binding similarity with E2 (0.905 Å and 
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0.562 Å respectively) and determined as described in the Materials and methods. The calculated 
RMSD for E2 between each of the parent compounds BuP and IsoBuP demonstrated comparable 
binding similarity as the metabolites (1.001 Å and 0.976 Å respectively). The calculated RMSD 
for each of the metabolite and parent compound pairs also indicated; high binding similarity with 




In addition to the numerous urine biomonitoring studies of parabens in diverse populations 
around the world [18-20, 28], in vivo studies using male rats suggest potential disruption of 
testosterone and sperm production from propyl- and n-butylparaben (BuP) exposures [51, 52]. In 
contrast, human epidemiological studies have not conclusively demonstrated that paraben 
concentrations in urine are associated with altered male steroid hormone levels or with indicators 
of sperm DNA damage [53, 54]. However, a common finding among studies measuring paraben 
compounds in urine is the several fold higher paraben exposure among females compared to 
males [15, 19, 53]. Urine studies have reported median concentrations of paraben compounds in 
urine of females generally at low nanomolar concentrations including 1.0 – 1.9 𝜇M   for 
methylparaben, 41.0 – 250.0 nM for propylparaben, and 3.1 – 3.6 nM for butylparaben [55, 56]. 
One report found significantly higher urine BuP levels (as a marker of higher exposure) being 
associated with shorter menstrual cycle length among female Japanese women age 19 to 22 
despite only reporting a median concentration of 3.6 nM for this compound [56] which is 2 to 3 
orders of magnitude lower than the EC50 for butylparaben as determined in our study. A larger 
study showed an association between higher levels of estrogen metabolites in urine, such as 
estrone sulfate and estrone glucuronide, and shorter menstrual cycles in a group of women that 
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were part of the Women’s Reproductive Health Study [57]. Therefore, the presence of estrogen 
mimicking compounds in systemic circulation, such as parabens, may have the potential to alter 
normal hormone or estrogen regulated processes such as those observed in ER-positive breast 
cancer. 
Similarly, it has been well documented that the paraben parent compounds, BuP and iso-
butylparaben (IsoBuP), induce estrogen-dependent breast cancer cell proliferation by ERα 
signaling and behave as ER agonists as observed in reporter gene and ER binding assays [12, 32, 
44, 50]. Two novel oxidized paraben metabolites were recently shown to be present in human 
urine samples which structurally appeared to meet the key amino acid hydrogen bonding 
requirements for ERα in complex with E2 [11, 13]. We also determined the chemical similarity 
of the oxidized metabolites, indicated by their Tanimoto coefficient (Tc) (Table 2.1), which were 
found to be comparable to known agonists, BuP and IsoBuP, relative to E2. Given these 
structural similarities of the oxidized metabolites and their parent compounds with E2, we 
characterized the potential estrogenic behavior of these novel paraben metabolites and provide 
evidence as to whether they can promote cell proliferation by an estrogen signaling mechanism. 
Using in vitro growth assays, we were able to demonstrate that the novel paraben 
metabolites 2OH and 3OH display characteristics of estrogenic behavior in ER-positive, 
estrogen-dependent human breast cancer cell lines. Although the 2OH and 3OH metabolites 
induce the proliferation of MCF-7 breast cancer cells, they appear to be less potent in T47D 
cells, particularly 3OH which required concentrations above 10 µM to induce significant cell 
proliferation. The proliferative ability of ER-negative MDA-MB-231 cells treated with the 
hydroxylated metabolites was not affected further suggesting that the metabolites induce cell 
proliferation via an ER signaling mechanism. Despite the paraben metabolite induced growth of 
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MCF-7 cells, 2OH and 3OH were found to exhibit estrogenic behavior that was less potent in 
comparison to their respective parent compounds. A possible explanation for the observed lower 
potency of the metabolites may be the result of lower membrane permeability and increased 
hydrophilic characteristics among the metabolites compared to BuP and IsoBuP indicated by 
their computationally derived log P values (Table 2.1). The presence of the second hydroxyl 
group on the 2OH and 3OH metabolites likely contributes to an increase in polarity making it 
more difficult to diffuse across the cell membrane compared their more lipophilic parent 
compounds. The correlation between membrane permeability and physiochemical properties of 
small molecules has been widely discussed elsewhere [58, 59]. 
We also investigated whether the cell proliferation of the estrogen-dependent breast 
cancer cells induced by the 3OH and 2OH paraben metabolites was due to ERα signaling. MCF-
7 cell proliferation induced by each of the paraben compounds was blocked in the presence of a 
pure-antiestrogen suggesting that the metabolites promote cell proliferation via ERα. We also 
examined the effect of the 3OH and 2OH metabolites on the transcriptional activity of an 
estrogen-inducible promoter by ERE-luciferase assay. We found that 2OH could significantly 
promote increased transcriptional activity at the concentrations tested; however, the 
transcriptional activity induced by 3OH was not statistically significant only at the 
concentrations tested. In addition, we observed significant metabolite-induced expression of the 
estrogen regulated gene, GREB1, which is a well characterized downstream target of ERα 
signaling. Increased expression of GREB1 was found to be time-dependent upon exposure to the 
metabolites as observed with the E2 positive-control. GREB1 expression induced by the 
compounds was blocked in the presence of a pure anti-estrogen for all tested paraben compounds 
which is consistent with the results from the growth assays as previously discussed. Lastly, our 
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in silico modeling data suggest that the paraben metabolites display a preference for docking to 
the ligand binding domain of ERα and demonstrate favorable interactions with key amino acid 
residues as seen in reported crystal structures of ERα with either E2, propylparaben, or BuP [11, 
13, 33]. Despite the favorable ligand binding domain interactions predicted from the docking 
experiments, the computationally derived partition coefficients and greater hydrophilic 
characteristics of the metabolites suggest that poor bioavailability might explain why the 
metabolites were not more potent than the parent compounds. It is important to note that our in 
silico approach cannot be used to make a distinction of whether the oxidized metabolites are 
indeed true agonists or antagonists. However, future work will focus on elucidating other 
potential binding modes or allosteric interactions among other hormone receptors and the 
oxidized metabolites. Collectively, these data, suggest that the novel 3OH and 2OH metabolites 
demonstrate behavior consistent with their being weak estrogens. 
Although the paraben metabolites were found to be generally less potent than their parent 
compounds, their calculated EC50
 values were still within a similar order of magnitude as their 
parent compounds according to previous reports. Furthermore, the extent of oxidative 
modification for the oxidized metabolites have been shown to be present ~2.3 fold or ~1.1 fold 
higher than their parent compounds in human urine for the 2OH and 3OH metabolites 
respectively [10]. This is especially important due to the presence of parabens in breast tissue 
[29] where the tissue concentrations of the oxidized metabolites is currently unknown. Charles 
and Darbre (2013) have previously shown that 27 % of breast tissue samples taken from patients 
with ER+PR+ primary tumors contained at least one measurable paraben compound that was 
above its lowest-observed-effect concentration in MCF-7 cells [29]. Although the breast tissue 
concentrations analyzed by Charles and Darbre were found to have median concentrations in the 
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low nanomolar range, some of the tissue samples were observed to have measurable paraben 
compounds in the micromolar range within 1 to 3 orders of magnitude of their experimental EC50 
values [29]. This same study also reported a few breast tissue concentrations that were at or 
above our experimentally determined EC50 for IsoBuP or near the EC30 for BuP [23, 29]. Despite 
these findings, healthy control tissue was not examined for paraben content making it difficult to 
interpret what potential biological effect the presence of these paraben compounds in breast 
tissue might have on ER-positive breast cancer. Furthermore, it is not well understood what 
potential effect these estrogen mimicking compounds might have in the context of ER-positive 
breast cancer patients who are on antiestrogen therapy, such as aromatase inhibitors (AIs), and 
whether total paraben exposure could contribute as possible mechanism of resistance for these 
patients. Therefore, combined exposure from the metabolites and their parent compounds should 
not be overlooked when being assessed in biomonitoring studies due to the risk of 
underestimating human exposure. Future work is needed to establish whether the metabolites 
would have a combined estrogenic effect in the presence of relevant concentrations of other 
paraben compounds that have been previously measured in tissue samples from patients with 
ER+ PR+ primary breast cancer [23, 29]. 
To our knowledge, this is the first report to characterize the estrogenic behavior of the 
novel paraben metabolites, 3-hydroxy n-butyl 4-hydroxybenzoate (3OH) and 2-hydroxy iso-
butyl 4-hydroxybenzoate (2OH). We have demonstrated that the oxidized 3OH and 2OH paraben 
metabolites induce breast cancer cell proliferation by estrogen signaling on the same order of 
magnitude as their parent compounds. However, the derived EC50 for the metabolites suggest 
that they are relatively less potent than their parent compounds. Given the lower potency of the 
metabolites relative to their respective parent compounds, existing regulatory standards and 
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industry trends toward safer alternatives may be adequate in limiting human exposure to paraben 
compounds. However, future biomonitoring studies should attempt to account for the metabolites 
when determining total daily intake averages to prevent an underestimation of an equally 
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Figure 2.1. Chemical structures of 17ß-estradiol, 3OH, and 2OH paraben metabolites. * - 


















Figure 2.2. n-Butylparaben and iso-Butylparaben induce breast cancer cell proliferation. 
MCF-7 and T47D cells were grown in steroid-deplete conditions as described in Methods 
section. PrestoBlue® cell viability assay was used as a surrogate to determine relative cell 
number. Estrogen dependent MCF-7 cells were treated with either n-butylparaben (BuP) (A) or 
iso-butylparaben (IsoBuP) (B) and T47D cells were treated with BuP (C) or IsoBuP (D) at the 
indicated concentrations. Growth curves represents percentage of cell growth compared to 
DMSO (vehicle) control (0 %). Points on dose response curve represent 6-day growth vs. vehicle 
treated control ± SE (n = 6 technical replicates). Each set of technical replicates were 
independently validated with a secondary experiment under identical treatment conditions (not 









Figure 2.3. 3OH and 2OH paraben metabolites induce breast cancer cell proliferation. 
MCF-7 and T47D cells were grown in steroid-deplete conditions as described in Methods 
section. PrestoBlue® cell viability assay was used as a surrogate to determine relative cell 
number. (A) MCF-7 cells were treated with either 3OH or (B) 2OH and (C) T47D cells were 
treated with 3OH or (D) 2OH at the indicated concentrations. Growth curves for A – D represent 
percentage of cell growth compared to DMSO (vehicle) control (0 %). Points on dose response 
curve represent 6-day growth vs. vehicle treated control ± SE (n = 6 technical replicates). Each 
set of technical replicates were independently validated with a secondary experiment under 




















Figure 2.4. 3OH and 2OH paraben metabolites do not induce androgen dependent cancer 
growth. LNCaP cells were grown in steroid-deplete conditions as described in Methods section. 
Crystal violet growth assay was used as a surrogate to determine relative cell number. LNCaP 
cells were treated with (A) 3OH or (B) 2OH and assayed for growth 6 days after treatment. 
Growth curves represents percentage of cell growth compared to DMSO (vehicle) control (0 %). 
Points indicate average growth of 6 replicates versus vehicle control ± SE (n = 6 technical 
replicates). Each set of technical replicates were independently validated with a secondary 
experiment under identical treatment conditions (not shown). Dotted line indicates growth 






Figure 2.5. 3OH, 2OH, n-Butylparaben and iso-Butylparaben do not induce a proliferative 
effect on ERα negative MDA-MB-231 breast cancer cells. MDA-MB-231 cells were grown in 
steroid-deplete conditions as described in Methods section. PrestoBlue® cell viability assay was 
used as a surrogate to determine relative cell number. MDA-MB-231 cells were treated with 
either (A) 3OH, (B) 2OH, (C) n-butylparaben (BuP), or (D) iso-butylparaben (IsoBuP) at the 
indicated concentrations. Growth curves represents percentage of cell growth compared to 
DMSO (vehicle) control (0 %). Points on dose response curve represent 4-day growth vs. vehicle 
treated control ± SE (n = 6 technical replicates). Each set of technical replicates were 





Figure 2.6. Pure anti-estrogen blocks 3OH, 2OH, respective parent compound induced 
breast cancer cell proliferation. MCF-7 cells were grown in steroid-deplete conditions as 
described in Methods section. PrestoBlue® cell viability assay was used as a surrogate to 
determine relative cell number. Growth induction by a fixed dose of either (A) (▪) 0.3 µM Iso-
butylparaben (solid line) or (▫) 2.15 µM 2OH (dashed line) or (B) by (▪) 1.2 µM Butylparaben or 
(▫) 8.22 µM 3OH was antagonized by the pure anti-estrogen, ICI 182,780 (ICI). ICI was added to 
final concentrations ranging from 1 pM – 1µM at log intervals. Growth curves represents 
percentage of cell growth compared to 2OH or Iso-butylparaben at the fixed concentrations 
indicated above. Data are normalized from maximum growth (100 %) to minimum growth (0 %) 
for each treatment. Points on dose response curve represent Points represent 6-day growth vs. 
proliferation with EC50 of indicated paraben without ICI ± SE (n = 6 technical replicates). Each 
set of technical replicates were independently validated with a secondary experiment under 






Figure 2.7. Time course induction of GREB1 expression in MCF-7 cells by the 3OH and 
2OH paraben metabolites. MCF-7 cells were assayed in steroid-deplete conditions. Cells were 
treated with a vehicle control (0.001% ethanol or 0.1% DMSO), or 100 pM E2, for 2, 4, and 6 
hrs. Neither ethanol or DMSO significantly affected expression levels compared to media (CCS) 
alone (data not shown). Cells were also treated at 10 µM with butylparaben (BuP), Iso-
butylparaben (IsoBuP), 3OH, and 2OH. Bars represent GREB1 expression versus vehicle-treated 
control using the ΔΔCT method. Bars represent the mean from 3 technical replicates ± SE. Each 
set of technical replicates were independently validated with a secondary experiment under 
identical treatment conditions (not shown). Statistical significance within each treatment group 
was determined by one-way ANOVA followed by Bonferroni posthoc analysis.  # = not 

















Figure 2.8. Induction of GREB1 expression in MCF-7 cells by the 3OH and 2OH paraben 
metabolites is blocked in the presence of ICI 182, 780. MCF-7 cells were assayed in steroid-
deplete conditions. Cells were treated with a vehicle control (0.001% ethanol or 0.1% DMSO), 
100 pM E2, or 100 nM ICI for 6 hrs. Neither ethanol or DMSO significantly affected expression 
levels compared to media (CCS) alone (data not shown). Cells were also treated at 10 µM with 
n-butylparaben (BuP), Iso-butylparaben (IsoBuP), 3OH, and 2OH alone or in combination with 
100 nM ICI. Bars represent GREB1 expression versus vehicle-treated control using the ΔΔCT 
method. Bars represent the mean from 3 technical replicates ± SE. Each set of technical 
replicates were independently validated with a secondary experiment under identical 
treatment conditions (not shown). Statistical significance between for treatments with and 




Figure 2.9. The 2OH paraben metabolite promotes significant ERE-luciferase 
transcriptional activity. The 2OH and 3OH paraben metabolites significantly induce ERE-
luciferase activity. MCF-7 cells were co-transfected with the ERE-luciferase construct and 
renilla reporter plasmid in steroid-deplete conditions and treated at the indicated concentrations 
for each compound. Relative firefly luciferase activity was plotted over renilla luciferase activity 
induced by treatment from each specified compound versus ethanol vehicle control for E2 and 
DMSO vehicle control for each paraben compound. Statistical significance between each 
indicated pair was determined by one-way ANOVA followed by Tukey posthoc analysis. Bars 
represent the mean from 3 technical replicates ± SE. Each set of technical replicates were 
independently validated with a secondary experiment under identical treatment conditions (not 



















Figure 2.10. 3OH and 2OH paraben metabolites dock to estrogen receptor α. Human estrogen 
receptor α ligand binding domain docked with (A) 2OH isomer (B) 3OH R isomer or (C) 3OH S 
isomer. 2OH and 3OH are colored orange and magenta respectively. 17ß-estradiol has been overlaid 
with each ligand in grey for comparison. Hydrogen bonds are represented as yellow dashes. Oxygen 
and nitrogen atoms are colored in red and blue respectively. Active site helices (H3, H5, H11, & 




Figure 2.11. 2D interaction diagrams for the 3OH and 2OH paraben metabolites. 2D ligand 
interaction networks for (A) 2OH (B) 3OH R and (C) 3OH S isomers. Dashed green lines 
indicate hydrogen bonds. All other relevant interactions are outlined in each figure legend. 
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(Tc) (Relative to E2) 
17ß-estradiol (E2) 3.71 1.000 
n-Butylparaben 3.12 0.524 
Iso-Butylparaben 3.12 0.527 
(3S)-3-hydroxy n-butyl 4-hydroxybenzoate 
(3OH) 
1.63 0.549 
(3R)-3-hydroxy n-butyl 4-hydroxybenzoate 
(3OH) 
1.63 0.556 
2-hydroxy iso-butyl 4-hydroxybenzoate (2OH) 1.66 0.530 
Partition coefficients and Tanimoto similarity scores were determined for each isomer of the 
parent and hydroxylated metabolites butylparaben. Calculator Plugins were used for structure 
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Homology Models of Mouse and Rat Estrogen Receptor-α Ligand-Binding Domain 
Created by In Silico Mutagenesis of a Human Template: Molecular Docking with 17ß-
Estradiol, Diethylstilbestrol, and Paraben Analogs 
Introduction  
 
Numerous toxicology studies depend on rodent in vivo models [1, 2] as well as in vitro 
screening assays [3-5] to identify and characterize suspected endocrine disrupting compounds 
(EDCs). Traditional methods of generating toxicity data for risk assessment that rely on animal 
models or even in vitro assays can quickly become too costly or time-consuming to adequately 
screen and establish toxicological profiles for the tens of thousands of chemicals cataloged by the 
United States Environmental Protection Agency [6]. Efforts are underway to minimize the use of 
rodent models and establish new approach methodologies [7] that could be used more routinely 
to screen and identify suspected EDCs via in silico approaches [8, 9]. However, attempts to 
establish in silico protocols for identifying EDCs that act on estrogen signaling pathways are 
hampered due to the lack of reported structural data for mouse or rat estrogen receptor-α (ERα) 
within the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) 
[10, 11].  
Interspecies sequence identities for the entire ERα receptor are 88.5% (human-mouse), 
87.5% (human-rat), and 97.5% (mouse-rat). For the ligand binding domain (ERα-LBD) alone, 
the interspecies sequence identities are 95.5% (human-mouse), 95.1% (human-rat), and 99.2% 
(mouse-rat) [12] (Figure 3.1). We therefore hypothesized that these receptor species should 
 90 
display similar 3D structures and exhibit comparable ligand binding interactions with known 
agonists. Although this contention appears logical and likely, subtle differences in the protein 
sequence could affect tertiary structure and/or ligand binding to a given receptor [13]. For 
example, several clinically relevant mutations resulting in single amino acid substitutions in the 
human ERα-LBD have been shown to confer a ligand-independent phenotype compared to the 
wild type ERα-LBD [14-16], which further demonstrates the apparent structural and functional 
sensitivity of the ERα-LBD to small differences in its primary sequence. 
To determine whether the differing residues among the rodent and human ERα-LBD 
receptors could be considered neutral substitutions, we created ERα-LBD structures for the 
unreported rodent species via in silico mutagenesis of a human ERα-LBD template. Structural 
improvement of these in silico models was achieved by energy minimization and molecular 
dynamics refinement in the YASARA molecular modeling suite [17]. The construction of these 
in silico receptors allowed us to address the lack of reported mouse and rat ERα-LBD structures 
and compare how each of these ERα-LBDs might interact with known or postulated ERα 
agonists using molecular docking simulations. Comparative docking into rodent and human 
ERα-LBDs was carried out with 23 compounds designated Group A ligands. These compounds 
included 17β-estradiol (E2), diethylstilbestrol (DES), 17 paraben analogs and 4 paraben 
metabolites (Figure 3.2, Table 3.1). 
Molecular docking of E2, the most potent endogenous estrogen in both humans and 
rodents [18, 19], with the human and rodent ERα-LBDs provided us with a point of comparison 
for analyzing ligand-residue interactions among different ERα-LBDs agonists. For further 
calibration, we included DES, a potent synthetic nonsteroidal ERα agonist [20] that has been 
used as a model compound in the characterization of EDCs with estrogenic activity [21].  
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Parabens (esters of p-hydroxybenzoic acid) constitute a class of chemicals that have 
received considerable [3, 22] and controversial [23, 24] attention as suspected EDCs. Although 
they are found in relatively low concentrations in human tissues and possess only weak 
estrogenic and antiandrogenic activity [25, 26], parabens are ubiquitous in the environment 
owing to their widespread use as preservatives in a variety of foods and personal care products 
[27]. However, apart from concerns about potential adverse health impacts of parabens, the main 
purpose of the present study was to use members of a homologous series of paraben compounds, 
paraben metabolites, E2, and DES as tools in molecular docking simulations to assess the degree 
of similarity of ligand binding between human and rodent ERα-LBDs. A set of experimental 
estrogenic activity data for the human ERα was also available for 13 of the parabens and E2 
[28], enabling us to compare these results with corresponding potencies derived from docking.  
Recently, it has been found that various substitutions in the benzene ring of n-butyl and 
n-octyl parabens, especially in the 3,5-position, result in decreased binding to human ERα with 
concomitant enhancement of antimicrobial activity [29]. This discovery opens up the possibility 
of replacing existing parabens with analogs that are more effective preservatives and even less 
likely to act as EDCs. Moreover, this publication provided us with an additional consistent set of 
experimental structure-activity data on paraben analogs for assessing the effectiveness of our 
docking protocols. Accordingly, we carried out docking of these 15 compounds (designated 
Group B ligands, Figure 3.3, Table 3.2) into the human ERα-LBD to determine the extent to 
which computationally predicted affinities agreed with experimentally determined binding 
potencies. 
A preliminary version of this work was presented at the 57th annual meeting of the 
Society of Toxicology [30].  
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Materials and Methods 
 
Receptor preparation with YASARA   
The crystal structure of the human ERα-LBD (Y537S) in complex with 17β-estradiol 
(PDB 3UUD) [31] was downloaded and prepared for docking with the YASARA molecular 
modelling suite (YASARA-Structure version 17.4.17 for Windows) [17]. This structure was 
selected as a template for creating homology models of mouse and rat ERα-LBD via in silico 
mutagenesis due to its high resolution (1.6 Å) and the presence of the Y537S mutated residue, 
which stabilizes the agonist-binding conformation of the protein without compromising the 
overall structure or agonist ligand-binding properties of the protein [31]. The Y537S residue in 
the human ERα-LBD template receptor was retained for the mouse and rat structures created via 
in silico mutagenesis. All crystallographic waters were removed, hydrogen atoms were added, 
bond orders were corrected for S-hydroxycysteine residues, missing loops were repaired [32], 
and only chain-A in complex with its 17ß-estradiol ligand (E2) was retained. Differing residues 
between protein sequences for human [33], mouse [34], and rat [35] ERα-LBD were identified 
by protein sequence alignments (Figure 3.1) performed with Geneious bioinformatics software 
(version 11.1.5 for Windows) [36, 37]. These residues in the human 3D structure were then 
mutated in silico using YASARA to create separate mouse and rat ERα-LBD receptors. The 
residue mutations for mouse were L306P, I326M, L327I, T334S, V368G, T371N, Q502R, and 
S527N. The residue mutations for rat were L306P, I326L, L327I, T334S, V368G, T371N, 
T483N, Q502R, and S527N. Side-chains of mutated residues were optimized with YASARA 
using the SCWALL method, which combines semi-empirical quantum mechanics, rotamer 
library, and steepest-descent algorithms [38].  
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For the human and rodent ERα-LBD receptors created via in silico mutagenesis, a cubic 
simulation cell was set to automatically encompass the entire receptor in YASARA plus an 
additional 2.5 Å margin in the x, y, and z directions. With the E2 ligand in the active site, each 
prepared receptor was separately subjected to energy minimization using the YASARA2 force 
field, which is based on AMBER14 with the addition of knowledge-based dihedral and 
interaction potentials [38]. The energy-minimized structure was subjected to a 500 ps molecular 
dynamics refinement in explicit water solvent using YASARA and the YASARA2 force field 
[39]. Each receptor and refinement step were analyzed for structural errors and scored using 
MolProbity [40, 41]. Based on their MolProbity scores, the best ERα-LBD receptor for human, 
mouse, and rat was chosen for docking comparisons among all three receptor species.  
 
Receptor preparation with UCSF Chimera 
All crystallographic waters were removed, hydrogen atoms were added, and missing 
loops were repaired with UCSF Chimera (version 1.11 for Windows) [42] as a graphical user 
interface for MODELLER using default settings. Only chain-A with its native E2 ligand was 
retained for further refinement. Differing residues between human, mouse, and rat ERα-LBD 
were identified as described in the previous section. Residue differences observed in either 
mouse or rat ERα-LBD were swapped using the Dunbrack rotamer library via UCSF Chimera to 
create separate receptors using the prepared human ERα-LBD structure as a template. All 
observed clashes among swapped residues were optimized by subjecting them to energy 
minimization in UCSF Chimera using default settings for each ERα-LBD receptor. Energy 
minimization of the entire receptor was performed for comparison using 100 steepest descent 
minimization steps and 10 conjugate gradient steps. Molecular dynamics refinement in explicit 
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solvent was performed with the YASARA molecular modeling suite with default settings using a 
500 ps simulation as described in the previous section. Each receptor and refinement step were 
analyzed for structural errors and scored using MolProbity [40, 41]. 
 
Receptor preparation with I-TASSER 
The protein sequence for mouse [34] and rat [35] ERα were uploaded to the I-TASSER 
online server (https://zhanglab.ccmb.med.umich.edu/I-TASSER/) for receptor assembly by 
iterative threading using default parameters [43]. I-TASSER does not produce a receptor with a 
ligand bound to it. Therefore, a cubic simulation cell was fitted around the entire mouse or rat 
ERα-LBD structure produced by I-TASSER plus an additional 5 Å margin in the x, y, and z 
directions. A docking simulation was performed with AutoDock Vina [44] for 100 runs using 
default parameters, and setup was conducted with YASARA as the graphical front-end [45] 
using the E2 ligand extracted from the crystal structure of human ERα-LBD (PDB 3UUD). The 
top pose for each docking run in the rodent receptors were selected for further structural 
refinement via energy minimization using the YASARA2 force field as described above. The 
energy-minimized structure was subjected to 500 ps molecular dynamics refinement in explicit 
solvent using YASARA with the YASARA2 force field as described above [39]. Each receptor 
and refinement step were analyzed for structural errors and scored using MolProbity [40, 41]. 
 
Selection and preparation of Group A and Group B ligands 
Group A ligands are shown in Figure 3.2. These 23 compounds included E2, DES, and 
21 paraben analogs. Many of the parabens in this group have been previously characterized in 
vitro in estrogen-dependent breast cancer cell lines or reporter assays, which have demonstrated 
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relatively weak estrogenic behavior for these compounds [3, 5, 22, 28]. We also included (R)- 
and (S)-3-hydroxybutyl 4-hydroxybenzoate (3OHR and 3OHS) and 2-hydroxy iso-butyl 
4-hydroxybenzoate (2OH) [46], metabolites of n-butylparaben (BuP) and iso-butylparaben 
(iBuP), which we recently characterized in vitro as weak estrogenic compounds in human ERα-
expressing breast cancer cell lines [47].  
Group B ligands are shown in Figure 3.3. These 17 compounds consisted of BuP and E2 
along with 15 parabens containing various substituents in the benzene ring [29].  
Initial structures for Group A and Group B ligands were generated using ChemDraw 
Professional version 17.1.0.105 for Windows and saved as CDX structure files. Each CDX file 
was imported into Chem3D Ultra version 17.1.0.105 for Windows and energy-minimized using 
the MMFF94 functionality in Chem3D Ultra to ensure that the structures had the correct orders, 
lengths, and angles for all bonds. The minimized structures were saved as PDB files for use in 
the docking simulations.  
Ligand PDB files were converted to SDF files using OpenBabel version 2.4.1 64-bit for 
Windows [48, 49] for calculation of pKa and solvent-accessible surface area (SASA) using 
SimulationsPlus ADMET_Predictor version 9.0.0.10 64-bit for Windows [50]. These values are 
listed in Table 3.1 (Group A ligands) and Table 3.2 (Group B ligands). 
  
Docking simulations  
Docking was performed with AutoDock Vina [44] using default parameters, and setup 
was conducted with YASARA as the graphical front-end [45, 51]. A cubic simulation cell (25 Å 
× 25 Å × 25 Å) was centered on the C9 carbon of E2 before removing the native ligand from 
each receptor and set as the search space for all test compounds, which were treated as flexible 
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ligands. The best pose of 25 runs was selected based on the most favorable free energy of 
binding (G) among poses in which the 4-hydroxy group of the ligand benzene ring was oriented 
toward the R394 and E353 residues in the receptor binding site for potential hydrogen-bond 
formation, as seen in crystal structures of PrP, BuP, and E2 [31, 52, 53]. Hydrogen-bond 
networks of the docked structures were optimized with YASARA [54], and protein structures of 
docking complexes were aligned with MUSTANG [55] before determining interspecies root-
mean-square deviation (RMSD) values for docked ligands. Throughout this paper, ligand 
RMSDs are reported as heavy-atom (all atoms except hydrogen) values that have been 
symmetry-corrected to reduce false negative docking results [56]. Protein RMSDs are reported 
as CA backbone values [57, 58].  
Because G for docking tends to be biased in favor of larger molecules [59], we have 
expressed potency derived from docking in terms of ligand efficiency (LE). Thus, 
LEdock = -G/Nh, where Nh = the number of heavy (non-hydrogen) atoms in the ligand) [60, 61].  
In order to compare LEdock values with experimental data, we calculated experimental 
ligand efficiencies using the general relationship, LEexp = p(Activity)/Nh, where LEexp = 
experimental ligand efficiency, p(Activity) = -log(Activity), and Nh = the number of heavy (non-
hydrogen) atoms in the ligand. This comparison requires self-consistent sets of experimental data 
obtained with a given method under the same assay conditions [60]. For Group A ligands, 
experimental activity data meeting these criteria were available for 14 of the 23 compounds in 
terms of EC20 values for transcriptional activation in an estrogen response element (ERE) 
luciferase reporter assay for human ERα [28]. For Group B ligands, experimental activity data 
were available for all 17 compounds (15 ring-substituted paraben analogs along with E2 and 
BuP) as IC50 values for binding to the human ERα receptor [29]. 
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Receptor screening and assessment of unknown rodent structures   
Prepared mouse and rat ERα-LBD receptors created with YASARA [17], UCSF Chimera 
[42], and I-TASSER [43] were scored and compared using MolProbity (Tables 3.4 and 3.5). 
Side-chain optimization and energy minimization of the entire ERα-LBD structure in YASARA 
produced the highest-scoring receptors with the fewest structural errors for ERα-LBD among all 
three receptor preparation methods. The highest-scoring rodent receptors prepared with 
YASARA were selected to determine ligand-binding similarity among human and rodent ERα-
LBD and to carry out the remainder of the docking simulations conducted in this study. 
Structural similarity of the highest scoring ERα-LBD receptors were determined by the 
template-modeling score (TM-score) [58]. The TM-align web server 
(https://zhanglab.ccmb.med.umich.edu/TM-align/) was used to perform a structural alignment 
and generate TM-scores among the three species of ERα-LBD used for calibration. The TM-
scores and receptor CA backbone RMSDs between human and mouse (TM-score: 0.99; RMSD: 
0.16 Å) or rat (TM-score: 0.99; RMSD: 0.17 Å) were determined. The TM-score between mouse 
and rat (TM-score: 0.99; RMSD: 0.03 Å) was also calculated. A TM-score of 1.00 indicates a 
perfect match [58], and a CA backbone RMSD < 1 Å is within the generally accepted range for 
equivalent protein structures [62]. Thus, our three prepared in silico ERα-LBD models displayed 
a high degree of structural similarity.  
The docking results for E2 were subjected to 3D protein alignment via MUSTANG in 
YASARA for human and mouse (Figure 3.4A) or human and rat (Figure 3.4B) ERα-LBD, which 
indicated a docking preference for the known active site of human ERα. Further receptor 
calibration was carried out by aligning the proteins associated with the DES docking poses in 
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YASARA with MUSTANG for human and mouse (Figure 3.4C) or human and rat (Figure 3.4D) 
ERα-LBD. Protein-aligned mouse and rat docking poses for E2 (Figure 3.4E) or DES (Figure 
3.4F) are likewise shown. Hydrogen-bonding interactions of E2 and DES with key side-chain 
residues in the ERα-LBD receptors are shown in Figure 3.4. The ligand RMSD values for the 
aligned docking poses of E2 and DES in Figure 3.4 are summarized in Table 3.3. Aligned mouse 
and rat ERα-LBD poses for docked E2 and DES were determined to have ligand RMSD values 
of 0.18 Å and 0.05 Å, respectively. Given that ligand RMSD values of 2.0 to 2.5 A are the 
traditional cutoff range for equivalent poses [63, 64], the extremely small values we obtained for 
E2 and DES to calibrate the prepared receptors indicate that our in silico mouse and rat 
ERα-LBD models produced virtually identical docking results among the human and rodent 
ERα-LBD structures. These calibrated structures were therefore selected for further analysis of 
ligand binding similarity. 
 
Statistical analyses  
 
GraphPad Prism 7.04 for Windows was used to create correlation and pyramid plots of 
ligand-receptor residue or atom contacts obtained from the docking results; it was also used to 
determine Pearson (r) or Spearman (rs) correlation coefficients (GraphPad Software, La Jolla 
California USA, www.graphpad.com). The Pearson r was used for normally distributed data, and 
the Spearman rs was used for non-normally distributed data as determined by the D'Agostino & 
Pearson and Shapiro-Wilk normality tests in Prism. Data sets were treated as non-normally 
distributed if they failed to pass one or both normality tests (alpha = 0.05). Summary statistics of 
non-normally distributed data are presented as median values with 95% confidence intervals 
(CI). Correlations of LEexp vs. LEdock were obtained using Pearson partial correlation (rp) 
computed with OriginPro 2018b 64-bit for Windows to correct for the Nh covariate (OriginLab, 
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Northampton, Massachusetts USA, www.originlab.com). The Sorensen similarity coefficient 
(Sc, expressed as a percentage; also known as the Dice or Sorensen-Dice coefficient) for each 
docking comparison of ligand-receptor atom or residue contacts was obtained with the following 
equation: Sc = [2(NAB)/(NA + NB)]  100], where NAB = number of contacts for both species, NA 
= number of contacts for species A, and NB = number of contacts for species B [65, 66]. Sc was 





Group A ligand RMSD values indicate overall agreement of docking poses between species 
 
Upon calibration of the prepared ERα-LBD structures shown in Figure 3.4, we used the 
Group A ligands shown in Figure 3.2 and Table 3.1 to determine ligand-receptor binding 
similarities among the refined human structure and in silico rodent models of the ERα-LBD.  
Our first comparison was an examination of the interspecies ligand RMSD values for 
each Group A compound (Table 3.3). Overall group RMSD values (median, 95% CI, n = 23) 
were 0.49 (0.21-1.82) Å (human-mouse), 1.19 (0.22-1.83) Å (human-rat), and 0.18 (0.12-0.34) Å 
(mouse-rat). By definition, RMSD (human-human) = 0.00 Å. Because the generally accepted 
RMSD range for equivalent docking poses is 2.0-2.5 Å [63, 64], the small values we obtained 
indicate excellent overall agreement in docking members of this set of ligands into human, 
mouse, and rat ERα-LBD receptors. In general, the calibration ligands, DES and E2, showed the 
most favorable ligand RMSD values among the compounds tested. Among the paraben 
compounds, n-pentyl through n-nonyl and iso-alkyl analogs generally displayed more favorable 
RMSD values than those with shorter or longer n-alkyl chains. This optimal behavior is likely 
due to a combination of factors, including an overall reduction and constriction of possible 
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translational motion of the relatively larger compounds within the active site, as well as their 
ability to fully occupy the available space in this binding pocket in a manner similar to 
endogenous ERα agonists such as E2. Experimental data on relative estrogenic potency of 
paraben analogs also suggest that optimal activity reflects an ideal juxtaposition of molecular 
size and hydrophobicity [28].  
An example of a relatively poor docking result is shown with n-butylparaben (BuP) 
docked to human ERα-LBD and aligned with the top docking pose for mouse or rat (Figure 
3.5A, 3.5B). The rather large ligand RMSD values for the top docking poses of BuP in Figure 
3.5 indicate comparatively incongruent ligand alignment in human vs. rodent ERα-LBDs.  
In contrast, the top docking pose for iso-butylparaben (iBuP), a structural isomer of BuP, 
was found to display a nearly perfect alignment between human vs. mouse or rat receptors as 
evidenced by visual inspection (Figure 3.5C, 3.5D) and by the ligand RMSDs (Table 3.3). The 
alignment for iBuP docked to mouse vs. rat was also found to have an exceptional ligand RMSD 
as likewise observed in the case of BuP docked to mouse vs. rat receptors (Figure 3.5E, 3.5F, 
Table 3.3).  
 
 
Numbers of interspecies ligand-receptor contacts are highly correlated 
Our next comparison was an exploration of the degree of interspecies correlations of the 
numbers of residue and atom receptor contacts for each compound in Group A. The numbers of 
ligand-receptor residue or atom contacts between human and mouse ERα-LBD among all 
Group A ligands tested were found to have Pearson r = 0.913 and 0.978, respectively (Figure 
3.6A, 3.6B). Even higher correlations were obtained with the numbers of ligand-receptor 
receptor or atom contacts between human and rat ERα-LBD (r = 0.925 and 0.986, respectively, 
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Figure 3.6C, 3.6D). Finally, the numbers of ligand-receptor residue or atom contacts between 
mouse and rat ERα-LBD gave the highest correlations of all (r = 0.945 and 0.990, respectively, 
Figure 3.6E, 3.6F). The extraordinary correspondence between the numbers of ligand-receptor 
interactions in mouse and rat ERα-LBDs agrees with the high level of sequence identity between 
the rodent species (Figure 3.1). Overall, with respect to the numbers of residue or atom 
ligand-receptor contacts, the mouse and rat ERα-LBDs were found to interact with the series of 
paraben analogs and known ERα agonists from Group A ligands in a manner highly similar to 
that of the human ERα-LBD. 
 
Interspecies ligand-receptor contacts arising from specific residues are highly similar 
 To assess how similarly Group A compounds interacted with specific residues within the 
active site of ERα, we calculated the interspecies Sorensen similarity coefficients (Sc) for the 
numbers of residue contacts for each compound docked into human, rat, or mouse ERα-LBD 
(Table 3.3). Rather than simply correlating the number of ligand-receptor residue contacts for a 
given ligand between two receptors, the Sc takes into account the specific residues in each 
receptor making contacts with the ligand. This analysis yielded an interspecies Sc value for each 
compound. As can be seen in Table 3.3, low RMSD values for a given compound tended to be 
reflected by correspondingly high Sc values.  
The group Sc coefficients (median, 95% CI) for all residue contacts among all Group A 
ligands for each pair of species were 96.8 (90.0-100)% (human-mouse), 97.7 (89.5-100)% 
(human-rat), and 100 (97.8-100)% (mouse-rat). These Sc values indicate an overall high degree 
of similarity between human and rodent ERα-LBDs as well as between mouse and rat 
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ERα-LBDs with respect to the numbers of residue contacts between ligands and receptors arising 
from specific residues.  
 In order to gain a clearer picture of interspecies similarity of ligand-receptor atom 
contacts by residue for all Group A compounds, we displayed the data in the form of “pyramid 
plots”, in like manner to the classic “population pyramids” used to visually categorize 
demographic information by comparing the numbers of people in different age groups by gender 
[67]. Here, we replaced age groups with protein residue sequence numbers, and we replaced 
genders with species. As can be seen in Figure 3.7, the remarkable interspecies similarity in 
ligand-receptor atom contacts by residue is readily apparent from the symmetry of the pyramid 
plots. Moreover, on a quantitative basis, Sc values were 96.9% (human-mouse), 93.5% (human-
rat), and 96.9% (mouse-rat), and rs values were 0.977 (human-mouse), 0.966 (human-rat), and 
0.991 (mouse-rat). These plots were also useful for assessing the relative prevalence of ligand-
receptor interactions in a set of ligands. For example, among Group A ligands, there were highly 
frequent hydrophobic interactions with L346, L387, and F404 and less frequent hydrogen 
bonding interactions with R394, E353, and H524. 
  Overall, the Sc values for numbers of residue contacts along with the pyramid plots and 
their associated Sc values and rs coefficients demonstrate that the Group A ligands give rise to 
sets of specific active site contacts that are highly similar and consistent across human and rodent 
ERα-LBDs. 
 
Group A LEdock values are highly correlated between species 
Interspecies correlation plots of LEdock values for Group A ligands are shown in Figure 
3.8A,B (human-rodent) and Figure 3.8E (mouse-rat). Each plot also shows the partial Pearson 
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correlation coefficients (rp) to determine the degree of correlation corrected for the covariate, Nh 
(number of heavy atoms). These values were 0.958 (human-mouse), 0.981 (human-rat), and 
0.960 (mouse-rat), demonstrating excellent interspecies agreement in the predicted strength of 
ligand interactions with the ERα-LBD receptors.  
It is also noteworthy that the three longest-chain parabens, DeP, UnDeP, and DoDeP, 
were clustered at the low end of the potency scale, below LEdock values of 0.35 kcal/mol/Nh.  
This result agrees with published in vitro data showing that these three compounds exhibited 
little or no estrogenic activity as assessed by transcriptional activation in an estrogen response 
element (ERE) luciferase reporter assay [28]. However, the LEdock scores for 4OH and MeP 
calculated from our docking results were near the top end of the scale, whereas these compounds 
were negative in the ERE assay. Explanations of the anomalous results for these low molecular 
weight compounds are provided below in the Discussion section.  
 
Group B LEdock values are highly correlated between species and decreased by ring 
substitution 
Interspecies correlation plots of LEdock values for Group B ligands are shown in Figure 
3.8C,D (human-rodent) and Figure 3.8F (mouse-rat). In these cases, values for OcP from Group 
A ligands were included along with values for BuP that were already part of Group B in order to 
enable direct assessment of the effect of ring substitutions on predicted ligand binding of both n-
butyl- and n-octylparabens. Values of rp were 0.957 (human-mouse), 0.964 (human-rat), and 
0.990 (mouse-rat), indicating strong interspecies correlations.  
Moreover, it was readily apparent from inspection of the plots in Figure 3.8C,D and 3.8F 
that the predicted efficiencies of ligand binding of all ring-substituted n-butyl- and n-
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octylparabens (2a through 2k) were less than that of BuP. Furthermore, the LEdock values of all 
of the ring-substituted n-octylparabens (3e through 3k) were less than that of OcP. Thus, 
molecular docking predicts that adding ring substituents to n-butyl- or n-octylparaben as shown 
in Figure 3.3 will decrease the avidity of binding of these ligands to human, mouse, and rat ERα-
LBD receptors. 
 
Human LEdock and LEexp values display good agreement for both Group A and Group B 
ligands 
Figure 3.9 shows correlation plots for human LEexp vs. LEdock for Group A and Group B 
ligands. Self-consistent experimental data sets were available for 14 of the 23 ligands in Group A 
[28] and all 17 of the ligands in Group B [29]. The rp values were 0.894 for Group A and 0.918 
for Group B, indicating good agreement between ligand efficiencies computed from molecular 
docking and those derived from experimental data. In addition, Figure 3.9B shows that both 
LEdock and LEexp values for all of the ring-substituted parabens fall below these values for BuP, 




The identification and characterization of suspected endocrine disrupting compounds 
(EDCs) using both in vitro and in vivo methods has been considered one of the major fields of 
toxicology research for several decades [68]. Parabens represent one category of suspected EDCs 
that have been investigated for their potential action on ERα and related hormone signaling 
pathways [28, 47]. Although paraben compounds are generally considered weak agonists of 
ERα, they are still being investigated to determine whether current exposures may lead to 
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adverse impacts on human health [24, 27, 69]. For example, an epidemiological study reported a 
possible association between increased BuP exposure and markers of sperm DNA damage in 
men [70]. Another study showed a possible dose-response relationship between higher paraben 
exposure and shorter self-reported menstrual cycle length among female Japanese university 
students [69]. In addition, the detection of parabens in numerous human tissues [27, 71-77] and 
their associations with possible endocrine disruption in humans further demonstrate the 
toxicological relevance of these compounds as test ligands in our study. These findings also 
highlight the need for the further development of in vitro and in silico screening methods for 
recognizing and categorizing EDCs.  
Among computational approaches, there have been other reports on molecular docking of 
parabens. While these studies differed from our investigation in several respects (e.g., fewer 
paraben compounds and/or targets other than ERα), they also provided an important degree of 
corroboration and additional insight into our results. For example, in a study of five n-alkyl 
parabens [78], docking of BuP into the human ERα-LBD was shown to have a comparatively 
high RMSD from the crystal structure owing to the relatively unconstrained n-butyl group being 
able to adopt multiple conformations, as noted in our present work. In other reports [79, 80], 
MeP, EtP, and BzP were found to exert estrogenic effects in a uterotrophic assay in rats, and 
docking was used to show that these compounds adopted apparent bioactive conformations in the 
human ERα-LBD, similar to our findings. In a study of interactions of parabens with the human 
androgen receptor [25], docking scores for n-alkyl parabens were found to be inversely 
correlated with chain length, as found in our study with estrogen receptors. Moreover, dividing 
their –G values by Nh to yield LEdock scores resulted in changing their relative ranking of 4OH, 
PhP, and BzP from 7, 2, and 1 to 1, 4, and 6, compared to our relative ranking of the same nine 
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compounds as 1, 5, and 6, respectively. Finally, a docking study has been conducted on the 
inverse antagonistic activity of five parabens against the estrogen-related receptor gamma (ERR-
γ) [26], which has recently been shown to function as a tumor suppressor in gastric cancer [81]. 
The binding pocket of ERR-γ is similar to that of ERα, and parabens were found to dock in 
the known agonist site in like manner to our docking poses of parabens in the ERα-LBD 
structures. 
Although ERß might have been examined in the present study, ERα would be expected to 
contribute to a greater proportion of effects observed by binding of an ER agonist. For example, 
only the expression of ERα, and not ERß, is currently used to make clinical decisions regarding  
ER‑positive breast cancer primarily due to the relatively poor understanding of the role of ERß 
within this tumor subtype [82]. Further study is needed to determine the extent to which 
structural differences or differential expression of these estrogen receptor subtypes might elicit 
an estrogenic response from exposures to exogenous ER agonists. 
The data presented in the present report demonstrate that our in silico mutagenesis 
modeling of mouse and rat ERα-LBD was effective in producing structures with minimal errors 
and show that paraben analogs, E2, and DES interact similarly with the human receptor relative 
to rodent receptors. We have also shown that our in silico receptor structures are capable of 
recognizing a series of weak ERα agonists and producing docking results that agree with in vitro 
data regarding their ability to bind to ERα and modulate estrogen signaling pathways [3, 5, 28, 
47, 53, 83]. Furthermore, our docking results indicate that rodent and human ERα would likely 
experience similar LBD interactions with ERα agonists. Accordingly, the sequence differences in 
the rodent LBDs could be considered neutral substitutions. Additionally, our in silico models 
were shown to be effective in corroborating previously reported relative potencies of 
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unsubstituted parabens [28] as well as ring-substituted parabens [29]. These findings support the 
validity of using in vitro and in vivo rodent models to characterize suspected human ERα 
agonists and highlight the valuable alternative methodology of pre-screening and identifying 
these compounds in silico prior to conducting in vivo studies. Lastly, the use of the Sorensen 
coefficient generated useful quantitative measures for assessing the similarity of ligand 
interactions with different species of receptors, and our adaptation of pyramid plots provides a 
graphical method for assessing the similarity or dissimilarity of ligand-receptor interactions 
between species. 
Nevertheless, there were some apparent anomalous findings among our results. In an 
experimental study comparing estrogenic activities of paraben analogs [28], MeP and the 
common paraben metabolite, 4OH, failed to elicit an estrogenic response, yet we obtained a 
positive docking result with this compound in the three species of ERα-LBD. The negative 
experimental result with 4OH is not surprising, given the fact that parabens are neutral esters, 
whereas 4OH is a carboxylic acid with an experimental pKa of 4.54 [84] and calculated pKa of 
4.01 (Table 3.1). Therefore, this compound would be ionized at a physiological pH of 7.4. 
Because of its negative charge, 4OH would be expected to encounter difficulty gaining access to 
the hydrophobic interior of the ERα; however, when docked in the active site, hydrogen bonds to 
the phenol group and hydrophobic interactions with the benzene ring would serve to stabilize the 
complex [78]. 
As shown in Figure 3.10A, the mean LEdock values obtained from the docking results of 
all three species of ERα-LBD displayed a strong negative correlation with the solvent-accessible 
surface area (SASA) of the Group A parabens analogs, including the metabolite, 4OH. In this 
plot, 4OH aligns with the paraben analogs as the compound with the highest LEdock value and the 
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lowest SASA. At the same time, a plot of mean LEdock vs. pKa (Figure 3.10B) shows that 4OH 
clearly stands apart from the paraben analogs, which span the full range of LEdock values with 
little change in pKa. However, it is important to note that AutoDock Vina does not make use of 
partial atomic charges [85], and the same result was obtained whether 4OH was docked as a 
neutral molecule or as an ionized species (data not shown).  
In comparison, Figure 3.10C shows a negative correlation between the mean LEdock 
values of the Group B paraben analogs with SASA, similar to what was observed with the Group 
A ligands. Note that in Figure 3.10D, there is no statistically significant correlation between 
mean LEdock values and pKa, yet this representation and the data in Table 3.2 show that eight of 
the 17 compounds would be ionized to some extent at physiological pH. In the case of Group B 
compounds, the ionized group would be a phenolic oxygen. Here again, whereas docking scores 
were inversely related to molecular size, they were indifferent to the potential of a given 
compound to ionize. 
Moreover, the discrepant relative ranking of 4OH potency came about from the simple 
calculation of dividing –G by the number of heavy atoms in the molecule (Nh) to generate 
LEdock values. The motivation for this calculation arises from the fact that docking scores tend to 
favor larger molecules, and the LE metric provides an expedient way to correct this bias [60, 61]. 
If the Group A ligands were ranked by –G rather than LEdock, 4OH would move from first to 
last place. Nevertheless, regardless of its relative ranking, 4OH would retain a docking score. 
Therefore, the compound would not be deemed completely inactive, in keeping with its weak 
estrogenic activity in mouse bioassays [86] and human breast cancer cell lines [87]. Moreover, 
the general notion of 4OH as a ligand in complex with proteins should not be surprising, given 
that it has been docked into human cyclooxygenase-2 (COX-2) [88], despite negative results in a 
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COX-2 dependent human smooth muscle cell assay [89]. Furthermore, 4OH is found as a bound 
ligand in a variety of enzymes, including carbonic anhydrase [90], p-hydroxybenzoate 
hydroxylase [91], and 4-hydroxybenzoate octaprenyltransferase [92]. Lastly, 4OH was found to 
have intermediate antagonistic activity among paraben analogs against the human androgen 
receptor [25], and when its reported docking score was converted to an LEdock value, its relative 
rank increased from 7th to 1st place out of nine compounds, similar to the results we obtained in 
the present study. 
Although LE values (LEdock and/or LEexp) should be used and interpreted with due 
caution [93, 94], their validity and utility have been well established and widely accepted [60, 
61, 95]. Nevertheless, when LE values are employed to select optimally binding ligands for a 
given receptor, it is important to recognize that, in general, LE is not a linear function of Nh [59]. 
In particular, based on compilations from large databases of ligand-receptor complexes, LE 
values decrease markedly within an Nh range of 10 to 20 [94]. Thus, the use of LE values for 
compound selection can be problematic, especially for small molecules such as 4OH and 
paraben analogs with relatively short alkyl chains, such as MeP. The problem of smaller ligands 
having disproportionately large LE values has given rise to a variety of compensatory methods 
with varying degrees of success [96]. The more effective methods for correcting LE according to 
molecular size depend on deriving parameters from curve-fitting plots of LE vs. Nh. Obtaining 
meaningful values for such parameters would require much larger data sets than the ones 
described in the present study. Moreover, it must also be borne in mind that the main purpose of 
our investigation was not to determine the receptor-binding capabilities of individual parabens or 
to assess their potential human health impacts, but to use these compounds as tools to evaluate 
the similarity of the human ERα-LBD structure to our homology models of mouse and rat ERα-
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LBDs. In this way, our use of LE correlations along with those of other variables helped to 
demonstrate the strong structural and implied functional correspondence between human and 
rodent estrogen receptors. 
In summary, we have demonstrated that in silico mutagenesis of a template receptor with 
high sequence similarity to a target receptor of unknown tertiary structure is an acceptable 
method that produces models with minimal structural errors and highly similar docking 
interactions to those observed in the template. In addition, we have made a novel application of 
the Sorensen similarity coefficient (Sc) to compare LBD interactions of docking targets. Our data 
suggest that the Sc could adopted as an additional screening metric with potential applications in 
toxicology as well as drug discovery and development. In addition, our adaptation of pyramid 
plots affords a new and useful graphical method for visualizing similarities in docking results. 
Whereas LE values can provide a basis for useful correlations, they should be interpreted with 
caution, especially for low molecular weight ligands. Future studies investigating suspected 
environmental ERα agonists should consider screening such compounds using in silico 






Figure 3.1. Multiple protein sequence alignment of human, mouse, and rat ER. Residues 
differing from the human in any sequence are shaded gray. Domains: A/B (AF1) = magenta; C 
(DNA binding) = yellow; D (Hinge region) = light red; E (Ligand Binding Domain /AF2; region 
encompassed by PDB 3UUD) = green; F (C-terminal extension of Ligand Binding Domain/AF2) 
= light blue. The “X” residues 381 and 530 marked with orange annotations in the human 
sequence are hydroxyCys that were kept as Cys in the mouse and rat homology models. S537 
marked with a red annotation in the human sequence is the Y537S mutation that was introduced 
to stabilize the agonist conformation in PDB 3UUD; the mouse and rat homology models were 
likewise mutated to serine residues at this site. Sequences were downloaded from Uniprot 
(www.uniprot.com). Alignment was carried out by Geneious 11.1.5 (Geneious, 2018; Kearse et 
al., 2012) using the Clustal-Omega algorithm. Domain assignments were adapted from Uniprot 




Figure 3.2. Structures of Group A ligands used for docking studies. R-groups for parabens 




Figure 3.3. Structures of Group B ligands used for docking studies. Compounds are parabens 
with various substituents in the benzene ring. Compound designations are the same as in 
(Bergquist et al., 2018) as listed in Table 3.2. R′ = butyl; R′′ = octyl. 
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Figure 3.4. Docking comparisons of known ERα agonist ligands in human and rodent ERα-
LBD receptors. (A) E2 human and mouse. (B) E2 human and rat. (C) DES human and mouse. 
(D) DES human and rat. (E) E2 docked into mouse vs. rat. (F) DES docked into mouse vs. rat. 
Ligand colors: gray = human, magenta = mouse, orange = rat. Hydrogen bonds are represented 
as yellow dashes. Oxygen and nitrogen atoms are colored red and blue, respectively. Active site 
helix labels (H5, H11, and H12) are displayed in bold face. Hydrogen-bonding residues are 







Figure 3.5. Docking comparisons of Group A paraben ligands in human and rodent ERα-
LBD receptors. (A) BuP human and mouse. (B) BuP human and rat. (C) iBuP human and 
mouse. (D) iBuP human and rat. (E) BuP mouse and rat. (F) iBuP mouse and rat. Ligand colors: 
gray = human, magenta = mouse, orange = rat. Hydrogen bonds are represented as yellow 
dashes. Oxygen and nitrogen atoms are colored red and blue, respectively. Active site helix 








Figure 3.6. Correlations of numbers of contacts for Group A ligands docked into human 
and rodent ERα-LBD receptors. (A) Human-mouse residue contacts. (B) Human-mouse atom 
contacts. (C) Human-rat residue contacts. (D) Human-rat atom contacts. (E) Rat-mouse residue 
contacts. (F) Rat-mouse atom contacts. Residue contacts = filled circles, atom contacts = open 
circles. Each data point is labeled with the ligand name (See Figure 3.2 and Table 3.1). The 




Figure 3.7. Numbers of ligand-receptor atom contacts by residue for Group A ligands docked into human and rodent ERα-
LBD receptors. (A) Human (blue bars on left) and mouse (green bars on right) receptors. (B) Human (blue bars on left) and rat (red 
bars on right) receptors. (C) Mouse (green bars on left) and rat (red bars on the right). The Sorensen similarity coefficient (Sc, 
expressed as a percentage) along with the Spearman correlation coefficient (rs) and associated p-value are shown in each panel. 







Figure 3.8. Human-rodent LEdock correlations for Group A and Group B ligands. (A) 
Human-mouse, Group A ligands. (B) Human-rat, Group A ligands. (C) Human-mouse, Group B 
ligands. (D) Human-rat, Group B ligands. (E) Mouse-rat, Group A ligands. (F) Mouse-rat, 
Group B ligands. LEdock = -G/Nh, where LEdock = ligand efficiency for docking, G = free 
energy of ligand-receptor binding from docking results, and Nh = number of heavy (non-
hydrogen) atoms in the ligand. Each point is labeled with the name of the ligand (Group A 
ligands = closed circles, see Figure 3.2 and Table 3.1; Group B ligands = open circles, see Figure 
3.3 and Table 3.2). The Pearson partial correlation coefficient (rp, to correct for the covariate, Nh) 




Figure 3.9. LEdock and LEexp correlations for Group A and B ligands with human ERa-
LBD. (A) Group A ligands (filled circles) with names (Figure 3.2, Table 3.1). (B) Group B 
ligands (open circles) with names according to Bergquist et al. (2018) (Figure 3.3, Table 3.2). 
LEdock = -G/Nh, where LEdock = ligand efficiency for docking, G = free energy of ligand-
receptor binding from docking results, and Nh = number of heavy (non-hydrogen) atoms in the 
ligand. The Pearson partial correlation coefficient (rp, to correct for the covariate, Nh) and 







Figure 3.10. Correlations for Group A and Group B ligands with physiochemical 
parameters.  (A) LEdock vs. SASA for Group A ligands. (B) LEdock vs. pKa for Group A ligands. 
(C) LEdock vs, SASA) for Group B ligands. (D) LEdock vs. pKa for Group B ligands. Group A = 
closed circles; see Figure 3.2 and Table 3.1 for names. Group B = open circles, see Figure 3.3 
and Table 3.2 for names. Each point = mean ± SEM, n = 3 for human, mouse, and rat. In most 
cases, the error bars fall inside the diameter of the data markers. LEdock = -G/Nh, where LEdock = 
ligand efficiency for docking, G = free energy of ligand-receptor binding from docking results, 
and Nh = number of heavy (non-hydrogen) atoms in the ligand. SASA = solvent-accessible 
surface area of the ligand (Å2). The Pearson correlation coefficient (r) and associated p-value are 
shown in each panel. In panel (B), note that 4OH is a carboxylic acid, pKa = 4.01, that would be 
ionized at pH 7.4. The other Group A ligands are neutral esters with pKa values for their phenol 
groups within a narrow range, whereas their LEdock values span a wide range. In panel (D), note 
that some of the ring substitutions in the Group B ligands result in considerable lowering of the 














MP Methyl 8.43 322.94 
EP Ethyl 8.54 353.49 
PrP Propyl 8.67 382.68 
BuP Butyl 8.78 412.14 
PeP Pentyl 8.88 441.39 
HxP Hexyl 8.96 471.17 
HpP Heptyl 9.02 499.83 
OcP Octyl 9.08 529.01 
NnP Nonyl 9.13 552.71 
DecP Decyl 9.18 581.77 
UnDecP Undecyl 9.22 611.46 
DoDecP Dodecyl 9.26 640.59 
iPrP Iso-propyl 8.61 378.45 
iBuP Iso-butyl 8.77 403.42 
iPeP Iso-pentyl 8.87 432.28 
PhP Phenyl 8.53 405.94 



















Established ERα agonists 
E2 17β-estradiol 10.06 457.02 
DES diethylstilbestrol 10.31 489.45 
a Unless designated otherwise, all alkyl groups are normal (n) straight 
chains. 
b Most acidic pKa computed with ADMET_Predictor 9.0. 














n-Butyl parabens    
BuP None 8.78 412.14 
2a 2,3,5,6-tetrafluoro 3.73 434.90 
2b 3,5-dichloro 5.28 465.74 
2c 3,5-dibromo 5.30 483.57 
2d 3-bromo 7.03 447.79 
2e 3,5-diiodo 4.69 508.60 
2f 3-iodo 6.68 460.43 
2g 3,5-dimethyl 8.94 471.89 
2h 3,5-di-tert-butyl 9.50 601.17 
2i 3,5-dihydroxy 7.51 431.45 
2j 3,5-dimethoxy 8.68 506.35 
2k 3,5-dinitro 2.96 482.96 
n-Octyl parabens    
OcP None 9.08 529.01 
3e 3,5-diiodo 5.08 625.49 
3g 3,5-dimethyl 9.27 588.38 
3i 3,5-dihydroxy 7.90 548.40 
3k 3,5-dinitro 3.87 599.88 
Established ERa agonist 
E2 None 10.31 457.02 
a Parent n-butyl and n-octyl paraben and 17β-estradiol (E2) names from 
Group A (Figure 3.2; Table 3.1). Ring-substituted paraben names from 
Figure 3.3 (Bergquist et al., 2018). 
b 4-position in each case occupied by a hydroxyl group. 
c Most acidic pKa computed with ADMET_Predictor 9.0.d 





Table 3.3. Interspecies ligand RMSD values and Sc indices for ligand-receptor 
residue contacts of Group A ligands docked into human, mouse, and rat ERα-LBD 
receptors. 
Compound 













Parabens       
MeP 1.82 1.83 0.08 84.8 84.8 100 
EtP 2.51 2.96 1.05 72.7 74.3 93.8 
PrP 1.20 1.33 0.47 84.2 89.5 95 
BuP 3.22 3.30 0.10 81.0 81.0 100 
PeP 0.31 0.21 0.19 100 100 100 
HxP 0.18 0.16 0.12 100 100 100 
HpP 0.21 0.13 0.13 100 100 100 
OcP 0.49 0.47 0.15 100 97.9 97.9 
NnP 0.23 0.27 0.23 100 100 100 
DecP 3.60 3.57 0.12 90.6 90.6 100 
UnDecP 3.45 1.19 3.52 96.0 98.0 93.9 
DoDecP 0.66 3.62 3.64 94.1 92.3 96.3 
iPrP 0.36 1.74 1.54 97.0 86.5 88.9 
iBuP 0.14 0.18 0.09 100 100 100 
iPeP 0.46 0.50 0.24 97.7 97.7 100 
PhP 1.79 1.72 0.13 95.5 97.7 97.8 
BzP 2.09 2.11 0.09 89.4 89.4 100 
Parabens metabolites       
4OH 0.15 0.27 0.34 96.8 89.7 93.3 
2OH 2.09 2.08 1.02 88.4 88.4 100 
3OHR 1.79 1.73 0.18 90.0 90.0 100 
3OHS 0.15 0.13 0.16 97.7 97.7 100 
Established ERα agonists       
E2 0.08 0.22 0.18 100 100 100 
DES 0.11 0.14 0.05 100 100 100 
a Symmetry-corrected heavy-atom interspecies ligand RMSD values for Group A ligands docked into 
mouse and rat ERα-LBD receptors. Overall group RMSD values (median, 95% CI, n = 23) were 0.49 
(0.21, 1.82) Å (human-mouse), 1.19 (0.22, 1.83) Å (human-rat), and 0.18 (0.12, 0.34) Å (mouse-rat). By 
definition, RMSD (human-human) = 0.00 Å. 
b Sorenson similarity coefficient (Sc) = [2(NAB)/(NA + NB)] x 100, where NA = number of contacts in 
receptor A, NB = number of contacts in receptor B, and NAB = number of contacts shared by receptors A 
and B. In this case, contacts are ligand-receptor residue contacts. Sc values (median, 95% CI, n = 23) for 
all ligands were 96.8 (90.0, 100)% (human-mouse), 97.7 (89.5, 100)% (human-rat), and 100 (97.8, 100)% 




Table 3.4. Comparison of MolProbity receptor quality assessment of refined mouse ERα-
LBD structures. 




Receptor Prep Method 



















































































































































C β deviations  






























































per chain, or 
≤5 % 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 
0 / 9 
(0.0%) 






















































































a Molprobity analysis carried out by the Molprobity web server (MolProbity, 2018; Chen et al., 2010). 
b MolProbity analysis statistics as defined by the Molprobity web server (MolProbity, 2018; Chen et al., 2010).  
c Molecular dynamics refinement performed with YASARA. 
d Energy minimization performed with YASARA. 
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Table 3.5. Comparison of MolProbity receptor quality assessment of refined rat ERα-LBD 
structures. 




Receptor Prep Method 
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a Molprobity analysis carried out by the Molprobity web server (MolProbity, 2018; Chen et al., 2010). 
b MolProbity analysis statistics as defined by the Molprobity web server (MolProbity, 2018; Chen et al., 2010).  
c Molecular dynamics refinement performed with YASARA. 
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Targeted Degradation of Activating Estrogen Receptor α Ligand-Binding Domain 
Mutations in Cell Models of Human Breast Cancer 
Introduction 
 
Breast cancer is currently the most commonly diagnosed malignancy among women in 
the United States (US) with an estimated 266,000 new diagnoses and 41,000 deaths in 2018 
alone [1]. Patients with estrogen receptor positive (ER-positive) breast cancer make up 
approximately 70% of all breast cancer diagnoses and are often treated with tamoxifen or an 
aromatase inhibitor (AI) during the first 5 years of adjuvant endocrine therapy using [2]. 
Although adjuvant endocrine therapy is  effective in lowering the rate of recurrence and disease-
free survival among ER-positive patients, ~20 % of patients treated with either tamoxifen, an AI, 
or both will still recur within 10 years of treatment [2, 3]. Interestingly, during the period of 5 to 
20 years following the cessation of endocrine therapy, ER-positive patients exhibit a persistent 
risk of recurrence that increases at a rate of ~1-2% every year irrespective of their nodal status 
and stage [4]. In vitro studies investigating the potential mechanisms of AI resistance have 
observed adaptation and maintained cellular proliferation of estrogen receptor α (ERα) 
expressing MCF-7 cells in long-term estrogen-deprived (LTED) conditions [5], and others have 
suggested that non-classical estrogens resulting from androgen metabolism could contribute to 
AI resistance [6].  
 However, the re-discovery of constitutively active ESR1 ligand-binding domain (LBD) 
somatic mutations in endocrine therapy resistant, metastatic ER-positive breast cancers proved to 
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be another likely mechanism of acquired resistance to endocrine therapy [7-9]. Two of the most 
common LBD mutations, Asp538Gly (D538G) and Tyr537Ser (Y537S), are detected at a 
frequency of ~30-40 % among patients resistant to endocrine therapy [10]. Given the rarity of 
these mutations in primary breast cancer [11] and their absence in matched primary samples 
from patients with metastatic disease, it has been proposed that the acquisition of ESR1 mutants 
may be a result of the selective-pressure of endocrine therapy that allows for tumors cells already 
harboring these mutations to survive [12]. Some ESR1 mutations have recently been reported in 
PDX models [13] and were found to occur naturally in LTED ER-positive cell lines [10] where 
the phenotype of maintained cell proliferation was observed in the absence of estrogen. 
Functionally, the LBD mutations were shown in vitro to induce the agonist conformation of ERα 
and promote constitutive activity of the receptor in the absence of a ligand as well as confer 
resistance to known antiestrogens [7, 8, 14, 15]. Fulvestrant is a common antiestrogen that is 
given to patients with advanced disease by intramuscular injection and has been designed to 
induce degradation of ERα via the ubiquitin-proteasome pathway [16]. Although Fulvestrant has 
displayed clinical benefit in patients with advanced stage breast cancer [17], the drug resistant 
phenotype of the ESR1 mutants demonstrate the need to develop more potent and selective 
downregulators of ERα that are also orally bioavailable. AZD9496 is a recent example of a 
compound that is an oral, non-steroidal ERα downregulator that has undergone a recent Phase I 
clinical trial where four patients were reported to have stable disease at 12 months of treatment 
[18, 19]. However, recent advancements in the Proteolysis Targeting Chimeras (PROTAC) 
method for developing small-molecules for targeted degradation of specific proteins [20] is a 
novel approach that may lead to the improvement of compounds like AZD9496 as well as the 
discovery new drug agents with greater potency such as the ones described in this report.             
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 Since the introduction of the PROTAC method in 2001 to induce efficient and targeted 
degradation of proteins [21], significant progress has been made towards developing similar 
PROTAC molecules for potential applications in leukemia and triple negative breast cancer [22-
24]. PROTACs achieve degradation by hijacking the ubiquitin-proteasome pathway where these 
bifunctional small molecules recruit a target protein and bring it near an E3 ubiquitin ligase to 
initiate the degradation process [25]. Although the ESR1 mutants are constitutively active in the 
absence of endogenous estrogens, they still are dependent on the presence of ERα to promote ER 
mediated cell proliferation. Therefore, the use of the PROTAC method to develop bifunctional 
molecules with a ligand specific for ERα linked to a ligand for Cullin-4A ligase complex should 
lead to a reduction in ER mediated cell proliferation.  
 In this chapter, we report the development ERD-148 as a novel degrader of ERα that is a 
more potent downregulator of ERα protein expression compared to Fulvestrant in both WT and 
monoclonal MCF-7s cell lines engineered to express the Y537S and D538G mutants using 
CRISPR-cas9 genome editing (cY537S and cD538G).  
 
Materials and Methods 
 
Chemicals 
17ß-estradiol (E2), tamoxifen (TAM), and Fulvestrant (ICI 182,780 - (ICI)) were purchased from 
Sigma-Aldrich Inc. (St. Louis, MO) with purity ≥ 98% determined by HPLC. E2 and ICI were 
dissolved to 10 mM in absolute ethanol and stored at -20 °C. The identity and synthetic 
procedures for compounds ERD-32, ERD-56, and ERD-148 are pending patent approval and will 
be released at a later date. Each PROTAC compound was dissolved to 10 mM in DMSO stored 
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at -20 °C. The final concentration of ethanol or DMSO did not exceed 0.1 % (v/v) in culture 
media. All compounds were stored protected from light. 
 
Cell lines and culture conditions  
MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells were obtained from the Tissue Culture 
Shared Resource (TCSR) at the Lombardi Comprehensive Cancer Center (Georgetown 
University, Washington, DC). All cell lines were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco/Life Technologies, Grand Island, NY) supplemented with 5% (v/v) 
fetal bovine serum (FBS) (Valley Biomedical Inc., Winchester, VA) for MCF-7 and MDA-MB-
231 cells, or 10% FBS medium for T47D and MDA-MB-468 cells, at 37 °C in a humidified 5 % 
(v/v) CO2 atmosphere. The identity of the cells was confirmed by short tandem repeat profiling 
by the TCSR and shown to be free of mycoplasma contamination. For assays in defined steroid 
deplete conditions, cells were repeatedly washed and grown in steroid-depleted media before 
proliferation assays (phenol red-free IMEM supplemented with charcoal stripped bovine serum – 
CBS) (Atlanta Biologicals Inc., Flowery Branch, GA) based on a previously described method 
[26].  
 
Creation of LBD mutation homology directed repair templates 
A 2,629 base pair fragment of the ESR1 gene containing exon 8, the ligand binding domain, was 
amplified using the HDR primers outlined in Table 4.1 from genomic DNA harvested from 
MCF-7 cells and cloned in pUC19 (Thermo Fisher Scientific, Waltham, MA). The forward and 
reverse primers also contained a 5’-KpnI and 5’-SalI sites respectively. Once the ESR1 gene 
fragment was cloned into pUC19, the wild-type sequence was verified by Sanger sequencing at 
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the University of Michigan Sequence Core using the above primers with M13 tails added, as well 
as with an internal sequencing primer. The ligand binding domain mutations Y537S and D538G 
in the pUC19-ESR1 exon8 plasmid were induced by site directed mutagenesis using the 
QuikChange II kit (Agilent technologies, Santa Clara, CA). The site directed mutagenesis 
primers were designed using their online mutagenesis sequencing tool 
(https://www.genomics.agilent.com/primerDesignProgram.jsp). The Y537S and D538G 
mutations were created using the primers listed in Table 4.1. The sequence of pUC19-wtESR1, 
pUC19-ESR1Y537S, and pUC19-ESR1D538G plasmids were verified by Sanger sequencing. 
Each pUC19-ESR1 plasmids was purified and isolated with Qiaprep Spin miniprep kit (Qiagen, 
Germantown, MD). Prior to transfection of the HDR template in MCF-7 cells, pUC19-
ESR1Y537S and pUC19-ESR1D538G plasmids were digested with KpnI/SalI and treated with 
Antarctic phosphatase (New England Biolabs, Ipswich, MA) and purified with QIAquick PCR 
Purification Kit (Qiagen, Germantown, MD). 
 
Creation of sgDNA targeting exon 8 of the ESR1 gene 
To target exon 8 of the ESR1 gene for CRISPR/Cas9-induced DNA mutation, we used the 
sequence CRISPR058819 as previously described [12]. This sequence was cloned into the 
plasmid pSpCas9(BB)-2A-GFP (Adgene plasmid 48140), a kind gift from the Zheng lab as 
previously described [27]. 
 
CRISPR/Cas9-induced ESR1 LBD mutation 
Using the mutated HDR templates and sgDNA plasmid, WT MCF-7 cells were transfected with 
2.5ug of sgDNA plasmid, and with either the digested pUC19-ESR1Y537S or the pUC19-
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ESR1D538G HDR templates using Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, 
MA) according to the manufacturer’s instructions. Transfected cells harboring the Y537S 
(cY537S) or D538G (cD538G) mutations were selected for by maintaining them in hormone 
deplete medium for four weeks before seeding them at a density of 1 cell / well in 96-well plates 
containing hormone deplete medium supplemented with 5% CBS using an MoFlo Astrios cell 
sorter at the University of Michigan Flow Cytometry Core. Surviving colonies were expanded in 
hormone deplete media for 3 months and screened by PCR amplifying and sequencing a 417 bp 
DNA sequence encompassing exon 8 at the University of Michigan Sequence Core using M13 
primers with the sequences 5’-AAGTGGGTCTTTAAACAGGA-3’ and 5’-
AGGAGACAGAATTTGGCTAA -3’ to identify the cells harboring the Y537S or D538G 
mutations (Figure 4.1). Verified cY537S and cD538G cells were maintained in steroid deplete 
IMEM/5% CBS media before treatments.   
 
PrestoBlue® cell viability assay 
For proliferation assays, MCF-7 and T47D cells were withdrawn from steroids as previously 
described [28] and plated in 5% CBS at 1000 cells / well and 2000 cells / well respectively in 96-
well plates and cultured overnight. cY537S and cD538G cells were seeded into 96-well plates at 
a density of 1000 cells / well in 5% CBS and allowed to attach overnight. MBA-MB-231 and 
MDA-MB-468 cells were plated in 5% FBS at 600 cells / well and 10% FBS at 1500 cells / well 
respectively in 96-well plates and cultured overnight. Cells were treated with the specified 
compounds at the indicated concentrations or the vehicle controls (ethanol or DMSO) diluted in 
IMEM supplemented with the CBS concentration for each cell line described above. After 
specified duration of treatment, cell viability was assessed using Presto Blue reagent 
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(ThermoFisher Scientific, Waltham, MA) according to manufacturer’s specifications. Plated 
cells were incubated for 3 hrs in the presence of 10 % (v/v) Presto Blue and absorbance was 
measured using a POLARstar Omega plate reader with the excitation/emission wavelengths set 
at 544/590 nm. Relative cell number was confirmed by crystal violet stain immediately after 
Presto Blue measurement as previously described [28]. Technical replicates were derived and 
analyzed from the same sample source across the indicated treatment conditions. Each set of 




MCF-7, cY537S, or cD538G cells were plated in steroid-deplete media at a density of 2 x 106 
cells in 10cm dishes. Whole cell lysates were isolated from each specified cell line 24 hrs after 
treatment with the indicated compounds. Cells were lysed using RIPA buffer (ThermoFisher 
Scientific, Waltham, MA) supplemented with Protease Inhibitor Cocktail Tablets and 
Phosphatase Inhibitor Cocktail Tablets (Roche Applied Science, Indianapolis, IN). Total protein 
from the lysates was quantified by the Bradford Assay (Bio-Rad, Hercules, CA). Twenty 
micrograms of reduced protein per lane was assayed on 4–20% Tris-glycine gradient 
polyacrylamide gels (Thermo Fisher Scientific, Waltham, MA), and transferred to a PVDF 
membrane according to manufacturer’s specifications. The PVDF membrane was blocked for 1 
hr with Blocking-Grade Blocker (Bio-Rad, Hercules, CA) and then incubated at 4°C overnight 
with primary antibody for ERα (sc-56836, Santa Cruz Biotechnology, 1:500). PVDF membranes 
were washed 3x over a period of 30 min with TBS containing 0.1% Tween 20 before incubating 
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the PVDF membrane with anti-mouse HRP-linked secondary antibody (7076S, Cell Signaling 
Technology, 1:10000) for 1 hr at room temperature. HRP-linked ß-Actin  
(12262, Cell Signaling Technology, 1:10000) was used a loading control. Blots were developed 
with Supersignal WestDura Extended Duration (ThermoFisher Scientific, Waltham, MA) on a 
Konica SRX-101A developer according to manufacturer’s specifications. 
 
RNA Expression Assay 
MCF-7, cY537S, or cD538G cells were plated in steroid depleted media at 350,000 cells / well 
in 6-well plates and cultured overnight before treatment with each specific compound. Total 
RNA was isolated using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA) according to 
the manufacturer’s instructions. Yield and quantity were determined by spectrophotometry 
(NanoDrop ND-1000). All samples were stored at -80 °C. Total RNA (1 µg) was reverse 
transcribed (RT) using Reverse Transcription System (Promega, Madison, WI) and the cDNA 
amplified in a 25 µl reaction containing Gene Expression Master Mix and gene specific primers 
(Thermo Fisher Scientific, Waltham, MA). GREB1 mRNA expression was measured using a 
TaqMan RT-PCR assay as previously described [26]. GREB1 expression was normalized against 




ERD-148 inhibits the proliferative ability of estrogen-dependent WT MCF-7 and cY537S 
and cD538G human breast cancer cells in steroid-free conditions 
To determine whether our series of PROTAC ERα degraders could inhibit the proliferative 
ability of human breast cancer growth, estrogen-dependent MCF-7 and T47D cell lines were 
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treated with either Fulvestrant (ICI) or the specified ERα degrader (Figures 4.2A & 4.2B, Table 
4.2). After a five-day treatment, cell viability data -confirmed by crystal violet staining- indicated 
that PROTAC degrader ERD-148 displayed comparable potency as ICI with an IC50 of 0.8 nM 
and 0.5 nM in WT MCF-7 and T47D cells respectively. The IC50 for ICI was determined to be 
1.3 nM and 0.6 nM MCF-7 and T47D cells respectively. ERD-56 and 32 were determined to be 
relatively less potent PROTAC degraders compared to ERD-148 with their IC50 values shown in 
Table 4.1. The observation of inhibited cell proliferation in both ER-dependent MCF-7 and 
T47D cell lines upon treatment with the PROTAC degraders suggests that this effect is not cell 
line specific.  
To confirm the estrogen independent and drug resistant phenotype of our CRISPR 
cY537S and cD538G cell lines, we conducted a five-day growth assay and treated each of these 
mutant cell lines with either E2, TAM, or ICI and compared their proliferative potential to WT 
MCF-7 cells (Figure 4.3A–4.3C). The proliferative ability of the cY537S and cD538G mutant 
cells did not appear to be affected by the addition of E2 at the indicated concentrations 
suggesting that they exhibited an E2 independent phenotype compared to WT MCF-7s and could 
proliferate in steroid-deplete media (Figure 4.3A). The IC50 for WT MCF-7, cY537S and 
cD538G cells treated with TAM was 0.33, 6.80, and 2.50 µM respectively (Figure 4.3B). The 
IC50 for WT MCF-7, cY537S and cD538G cells treated with ICI was 0.85, 5.78, and 4.30 nM in 
respectively (Figure 4.3C). The relatively lower potency of the antiestrogens, TAM and ICI, in 
mutant cY537S and cD538G treated cells suggest that they display a drug resistant phenotype 
compared to WT MCF-7 cells which was consistent with previous reports [15]. 
Once we determined that our mutant cY537S and cD538G cells exhibited an E2 
independent phenotype, we attempted to evaluate the relative potency of the PROTAC degraders 
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compared to WT MCF-7 cells (Figures 4.2C, 4.2D, and Table 4.2). Compound ERD-148 was 
found to have comparable potency as ICI in cY537S cells with IC50 values of 10.5 and 4.2 nM 
respectively. A similar trend was also observed cD538G cells between compound ERD-148 and 
ICI with their IC50 shown in Table 4.2. As expected from the growth assay data seen in Figures 
4.3B and 4.3C, there appears to be evidence of resistance to ERD-148 in the mutant cells versus 
WT MCF-7 cells indicated by the shift in the IC50 to higher concentrations. This apparent 
resistant phenotype was also observed for PROTAC degraders ERD-56 and 32 with their IC50 
values summarized for each cell line in Table 4.2.         
   
ERD-148 shows evidence of marginal non-specific toxicity in non-estrogen receptor α 
expressing cell lines  
To investigate potential signs of non-specific toxicity and whether ERD-148 was inhibiting cell 
proliferation due to antagonism of ER-mediated cell growth, we treated non-ERα expressing 
MDA-MB-468 and MDA-MB-231 cells with each PROTAC degrader and ICI (Figure 4.4A & 
4.4B). As seen in Table 4.2, the IC50 for ERD-148 and ICI are log shifted ~1-3 orders of 
magnitude to higher concentrations in the non-ERα expressing cells compared to the IC50 values 
as determined in WT MCF-7 cells. This data suggests that off-target effects may be occurring at 
doses greater than 100 nM for ERD-148 and that concentrations near 1 nM may inhibit WT 
MCF-7 cell proliferation via antagonism of ERα. There appears to be some separation of the IC50 
values for ERD-56 and 32 between the non-ERα and ERα expressing cells, however, cell 
proliferation that is inhibited near these IC50 concentrations may due to a combination of both 
non-specific toxicity and ERα antagonism for these two compounds.        
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PROTAC degraders induce downregulation of ERα protein expression in WT MCF-7, 
cY537S, and cD538G human breast cancer cells lines 
To determine if our series of PROTAC degraders were inhibiting the proliferative ability of ER-
positive cell lines by downregulating the expression of ERα, we treated WT MCF-7 and the cells 
expressing mutant cY537S and cD538G for 24 hrs with each PROTAC degrader and performed 
a western blot assay (Figure 4.5A & 4.5B). Treatment with compounds ERD-56, 32, and ICI at 
300 nM resulted in relatively lower levels of ERα expression in WT MCF-7 cells versus DMSO 
control (Figure 4.5A). These same compounds did not appear to be as effective in 
downregulating ERα expression at 300 nM in the mutant cell lines as indicating by the 
comparable protein bands for the DMSO control and the treatments (Figure 4.5A). PROTAC 
degrader ERD-148 downregulated ERα expression at concentrations as low as 1nM in WT MCF-
7 cells and appeared to do so more effectively than ICI (Figure 4.5B). Comparable ERα protein 
bands were seen among the DMSO control and the indicated treatment conditions in the mutant 
cell lines (Figure 4.5B) suggesting that there is some resistance to ERD-148 which is consistent 
with the growth assay data shown in Figure 4.2. Of the PROTAC compounds tested, ERD-148 
showed the most effective downregulation of ERα and was superior to ICI. 
   
PROTAC degraders downregulate mRNA expression of an ERα regulated gene, GREB1, in 
WT MCF-7, cY537S, and cD538G cells lines 
To determine if the PROTAC degraders were inhibiting the proliferative ability of the ER-
positive cell lines by antagonizing ERα, we performed RT-PCR to measure the relative 
expression of a downstream target of ER signaling, GREB1, in ER-positive treated cells (Figure 
4.6A – 4.6F).  WT MCF-7 cells treated with ERD-56 and 32 at 100 nM show significant 
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downregulation of the ER regulated gene, GREB1, versus the 50 pM E2 positive control at 24 hrs 
(Figure 4.5A). ERD-148 was able to achieve significant downregulation of GREB1 expression at 
concentrations as low 10 nM in WT MCF-7 cells versus 50 pM E2 treated cells (Figure 4.6B). 
Consistent with our previous observations, there appears to be evidence of resistance to ERD-56 
and 32 in the cY537S cells but significant downregulation of GREB1 was observed at 300 nM in 
both mutant cell lines treated with ERD-56 (Figure 4.6C & 4.6E). Similarly, evidence of 
resistance was seen in cY537S treated with ERD-148 at 10 nM but significant downregulation of 
GREB1 was reached at 100 nM treatment with ERD-148 in both mutant cell lines (Figure 4.6D 
& 4.6F). WT MCF-7 and mutant cells treated with ICI showed significant downregulation of 
GREB1 at all concentrations tested (p<0.0001) (Figure 4.6A – 4.6F). Of the PROTAC 
compounds tested, ERD-148 was found to downregulate the expression of GREB1 most similar 
to ICI. 
 
Addition of 17ß-estradiol competes with the PROTAC Degraders  
To provide additional evidence that ERα antagonism was the primary mechanism of these 
PROTAC degraders, we co-treated each ER-positive cell line at a fixed dose with each indicated 
degrader and increased the dose of E2 logarithmically (Figure 4.7A – 4.7C). WT MCF-7 and the 
mutant cell lines all responded with increased cell proliferation upon exposure to higher doses of 
E2 while co-treated with each PROTAC compound. The observation of increased cell 
proliferation suggests that E2 competes with the PROTAC compounds for ERα and that cell 
inhibition achieved by these degraders is reversible in the presence of a pure agonist given that 





In this chapter, we investigated the mechanism by which a series of PROTAC degraders inhibit 
the proliferative ability of ERα expressing breast cancer cell lines. ERD-148 was determined to 
be the most potent in our series of PROTAC compounds and downregulated the expression of 
ERα superior to Fulvestrant in WT MCF-7 and MCF-7 cells harboring the CRISPR/cas9 knock-
in LBD mutations. The expression of a critical ER-regulated gene, GREB1 [26, 30], was also 
found to be significantly downregulated in ER-positive cell lines upon exposure to ERD-148 in a 
manner comparable to Fulvestrant. Increased cell proliferation was observed in ER-positive cells 
co-treated with ERD-148 and E2 indicating that estrogen competes for the ERα receptor and 
suggests that the primary mechanism of these PROTAC compounds is ER antagonism. The ER-
negative, estrogen-independent cell lines treated with ERD-148 showed evidence of minimal 
non-specific toxicity at concentrations above its ~IC90 which highlight the therapeutic potential 
for ERD-148.   
Breast cancer cells which are ER-positive and HER2-negative generally rely on the 
expression of the hormone receptor, ERα, to promote ER-mediated cell proliferation [26, 30]. 
Pharmacological interference of ERα signaling or the inhibition of E2 hormone synthesis in vivo 
are recognized as effective methods to treat ER-positive breast cancer, however, acquired 
resistance to endocrine therapy is a common occurrence [2-4]. Previous publications have 
indicated the potential for ER-positive breast cancer cell lines to adapt to estrogen deprived 
conditions [5, 10, 31] and a significant number of patients with advanced disease have developed 
LBD mutations in ERα that may allow ER-positive tumor cells to proliferative in the absence of 
endogenous estrogens [7-9, 12]. Previous studies have also suggested that these LBD mutants 
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reduce the efficacy of ER antagonists [15] and highlight the need to develop more potent and 
selective ER antagonists to improve overall patient outcomes.  
  Although patients with advanced ER-positive breast cancer initially respond to endocrine 
therapy with drugs such as Fulvestrant [17], many of these patients will ultimately progress 
while on treatment [32-34] potentially through heterogeneous resistance mechanisms [34-36]. 
The absence of ESR1 LBD mutations detected in primary breast cancers has led to the theory that 
the selective pressure of endocrine therapy may promote the outgrowth of low-frequency sub-
clones already harboring these mutations, and these cells exhibit reduced sensitivity to ERα 
antagonists [12, 37]. If these mutations are a result of clonal evolution, then more potent and 
orally bioavailable ER antagonists that are superior to Fulvestrant [18], or alternative 
combination therapy options need to be explored. Combination therapy of small molecule 
inhibitors of essential coactivators of ER-mediated cell proliferation, such as SRC-3 which is 
recruited by ERα [38], with ERα downregulators is one approach that has been proposed that 
may offer therapeutic potential for patients with tumors expressing ESR1 mutants [39]. Similarly, 
other reports have shown some therapeutic potential in models of endocrine therapy resistant 
breast cancer co-treated with ER antagonists and inhibitors of cyclin dependent kinases 4 and 6 
[40]. Further in vivo testing of ERD-148 and the development of more potent iterations of this 
compound will be needed before clinical trials can be conducted to determine the clinical benefit 
of ERD-148 alone or in combination with drugs inhibiting other oncogenic targets.        
In conclusion, we have presented preclinical data characterizing a series of synthetic 
small-molecules designed via the PROTAC method for targeted chemical knockdown of ERα. 
Overall, compound ERD-148 demonstrated the greatest therapeutic potential in ER-positive 





Figure 4.1. ESR1 sequence alignment of exon 8 in WT MCF-7 and mutant cell lines. Sanger 
sequencing was performed on genomic DNA isolated from indicated cell lines as described in 
the Materials and Methods. Dashed red boxes and black arrows indicate location of mutated 
nucleotides in each labeled cell line. Alignment and visualization of Sanger sequencing results 




Figure 4.2. PROTAC ERα degraders inhibit the proliferative ability of ER-dependent 
breast cancer cell lines. (A) WT MCF-7, (B) T47D, (C) cY537S and (D) cD538G cells were 
grown in steroid-deplete media as described in the Methods section and treated with the 
indicated PROTAC degraders. Growth curves for A – D represent percentage of cell growth 
compared to 50 pM E2 treated WT MCF-7 or DMSO (vehicle) treated mutant MCF-7 as control 
(100 %). Points on dose response curve represent 5-day growth vs. control ± SE (n = 6 technical 
replicates). Each set of technical replicates were independently validated with a secondary 
















Figure 4.3. ERα mutants show evidence of estrogen independent growth and resistance to 
antiestrogens. WT MCF-7, cY537S, and cD538G cells treated with either (A) 17ß-estradiol, (B) 
tamoxifen, or (C) Fulvestrant. Cells were grown in steroid-deplete media as described in the 
Methods section. Growth curves for B and C represent percentage of cell growth compared to 50 
pM E2 treated cells control (100 %). Points on dose response curve represent 5-day growth vs. 
control ± SE (n = 6 technical replicates). Each set of technical replicates were independently 
validated with a secondary experiment under identical treatment conditions (not shown). 
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Figure 4.4. PROTAC ERα degraders demonstrate evidence of marginal non-specific 
toxicity in non-ERα expressing cell lines. (A) MDA-MB-468 and (B) MDA-MB-231 cells 
were grown in DMEM/5% FBS medium as described in the Methods section and treated with the 
indicated PROTAC degraders. Growth curves for A and B represent percentage of cell growth 
compared to DMSO (vehicle) control (100 %). Points on dose response curve represent 4-day 
growth vs. control ± SE (n = 6 technical replicates). Each set of technical replicates were 









Figure 4.5. PROTAC ERα degraders downregulate the expression of ERα in WT MCF-7 
and mutant cell lines. WT MCF-7, cY537S, and cD538G cells were grown in steroid-deplete 
media as described in Methods section. Relative ERα expression was determined by western blot 
assay and ß-actin was used as the loading control. (A) Cells were treated with either Fulvestrant 
(ICI), ERD-56, or ERD-32 for 24 hrs at the specified concentrations. (B) Cells treated with either 





















Figure 4.6. PROTAC degraders inhibit GREB1 mRNA expression in WT MCF-7 and 
mutant cell lines. (A-B) GREB1 mRNA expression for WT MCF-7, (C-D) cY537S, and (E-F) 
cD538G cells were assayed in steroid-deplete media after a 24 hr exposure to each specified 
compound. Cells were treated with a vehicle control (DMSO), 50 pM E2, Fulvestrant (ICI), or 
the indicated PROTAC degrader. Bars represent GREB1 expression versus DMSO control for 
WT MCF-7, cY537S, and cD538G cells using the ΔΔCT method. Bars represent the mean from 
3 technical replicates ± SE. Statistical significance was determined by one-way ANOVA 
followed by Tukey post-hoc analysis. Reference for significance is 50 pM E2 for panels A – B 
and DMSO for C – F. E2 (50pM) is required to stimulate the ER pathway in MCF-7 cells under 
steroid-deplete conditions. * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001.  
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Figure 4.7. Addition of 17ß-estradiol competes with the PROTAC Degraders. (A) WT 
MCF-7, (B) cY537S, and (C) cD538G cells were grown in steroid-deplete medium as described 
in the Methods section. Each cell line was co-treated at a fixed dose of the identified IC50 for 
each PROTAC degrader and with the indicated concentrations for E2. Growth curves for A – C 
represent percentage of cell growth compared to IC50 of each degrader alone control (0 %). 
Points on dose response curve represent 5-day growth vs. control ± SE (n = 6 technical 
replicates). Each set of technical replicates were independently validated with a secondary 
experiment under identical treatment conditions (not shown). 
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Table 4.1 List of primer sequences for CRISPR-cas9 generation of ESR1 LBD mutant 
cell lines. 
Primers Sequences 
HDR forward cloning 5’-ATTGGTACCGGCAGCAGAGTTGTGGCTAGTGGAG-3’ 
HDR reverse cloning 5’-AAGTGTCGACCAGGGTGCTGGGCCAATTGTAGGAAC-3’ 
HDR internal sequencing 
primer 
5’-TGAATGCATTTAGGTCCTAT-3’ 
Y537S mut Top 5’-GTGGTGCCCCTCTCTGACCTGCTGCTG-3’ 
Y537S mut Bottom 5’-CAGCAGCAGGTCAGAGAGGGGCACCAC-3’ 
D538G mut Top 5’-GTGGTGCCCCTCTATGGCCTGCTGCTG-3’ 




Table 4.2 List of IC50 values for PROTAC degraders cell line. 
IC50
  (nM) 
WT 
MCF-7 







Fulvestrant 1.1.3 0.6 4.2 3.8 3667.0 NC 
ERD-148 0.8 0.5 10.5 6.1 462.2 4630.0 
ERD-56 39.9 77.8 242.4 118.0 928.0 724.0 
ERD-32 89.0 1200.0 467.3 109.0 1208.0 6183.0 
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Conclusions and Future Directions 
Although adjuvant endocrine therapy is an effective treatment option for most ER-
positive breast cancer patients, breast cancer recurrence is still an ongoing clinical problem [1]. 
Sikora et al. suggested that alternative estrogens, arising from androgen metabolism, may 
contribute to AI resistance and partially explain why a significant number of patients will 
experience a recurrence within 10 years of receiving adjuvant endocrine therapy [2]. The data 
presented by Sikora et al. is just one example that highlights the importance of identifying 
related estrogen mimics in the context of ER-positive breast cancer recurrence and AI resistance. 
Similarly, determining what role suspected EDCs may have on AI resistance and breast cancer 
progression is relevant to elucidating alternative mechanisms of breast cancer recurrence. For 
example, the detection of weak ER agonists in breast tissue, such as parabens [3, 4], has 
contributed to much of the controversy and debate regarding the suspected role of EDCs in 
breast cancer and endocrine disruption. Additionally, the discovery of commonly reoccurring 
ESR1 LBD mutations in metastatic breast tumors may explain why endocrine therapy fails 
numerous patients and why they are associated with poor clinical outcomes [5].  
To date, most toxicology studies have focused primarily on characterizing the estrogenic 
behavior of unmetabolized short-chain paraben compounds [6-8]. The research presented in this 
dissertation tested the hypothesis that recently identified urinary human metabolites of n-
butylparaben (nBuP) and iso-butylparaben (iBuP) may also exhibit weak estrogenic behavior. 
We report that oxidized metabolites of nBuP and iBuP, 2-hydroxy iso-butyl 4-hydroxybenzoate 
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(2OH) and 3-hydroxy n-butyl 4-hydroxybenzoate (3OH), were found to exhibit weak estrogenic 
behavior in vitro [9]. The discovery of weak estrogenic behavior among these paraben 
metabolites are relevant in the context of risk assessment for several reasons. First, the 2OH and 
3OH metabolites were originally detected in human urine samples at concentrations which were 
~2.3 or 1.1 fold higher than their parent compounds for the metabolites, respectively [10]. Higher 
urinary concentrations of these metabolites are likely due to increased water solubility that would 
be attributed to their oxidative modifications as compared to the parent compounds which are 
relatively more lipophilic. Given that our data has shown that these metabolites are weak 
estrogens, these compounds might contribute to an equal or greater proportion of observed 
associations between other parabens and their associated adverse health outcomes [11-13]. 
Furthermore, the recent discovery of these metabolites implies that previous biomonitoring and 
exposure studies were unknowingly underreporting measured concentrations of nBuP and iBuP 
in humans. Therefore, future studies should attempt to account for the existence of these 
metabolites, either by direct measurement or the inclusion of a correction factor [10], when 
making conclusions about the extent of human exposure to nBuP and iBuP.  
Likewise, it is unknown whether these urinary paraben metabolites are present in human 
adipose or breast tissue where their parent compounds have been detected [3, 14]. If it is 
determined that the 2OH and 3OH metabolites are also present in human tissues, such as the 
breast, in vitro studies should examine whether there is evidence of estrogenic additivity or 
synergism between the metabolites and the parent compounds. The need to investigate the 
potential combined estrogenic effect attributed to these metabolites is relevant considering the 
findings from a prior report that conducted mixture studies of paraben compounds in ER-
dependent MCF-7 cells. This in vitro mixture study found that MCF-7 cells exposed to 
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representative breast tissue concentrations of parabens near their no observed effect 
concentrations could promote increased cell proliferation more effectively in combination with 
several parabens rather than as single compound exposures [15]. Thus, the potential combined 
exposure among the paraben metabolites and other parabens commonly detected in humans 
should not be overlooked in the context of risk assessment. Although it is possible that the 
influence of estrogenic EDCs is dependent upon the stage of ER-positive breast cancer and they 
may have a limited role in advanced disease. Further research is needed to conclusively 
demonstrate that local tissue concentrations of parabens are mechanistically involved in 
progression and recurrence of ER-positive breast cancer beyond their mere presence in these 
tissues.    
Whether parabens are involved in disease progression of ER-positive breast cancer or 
not, further work is needed to identify uncharacterized EDCs and steroid hormone mimics for 
evidence of estrogenic behavior. Although most toxicology studies often rely on in vitro or 
rodent models to characterize and identify estrogenic compounds, this approach is inherently too 
time consuming and costly to screen the tens of thousands of compounds currently cataloged by 
the US EPA [16]. Recently, there has been considerable effort to minimize the use the rodents 
and animals and utilize in silico-based approaches for toxicological profiling. Although there is 
increasing acceptance of in silico-based approaches for compound screening and identifying 
estrogenic EDCs, efforts to develop in silico protocols are hampered due to the lack of reported 
structural data for mouse or rat ERα. To address this knowledge gap, we have demonstrated that 
in silico mutagenesis of a human template ERα-LBD is a valid approach to develop in silico 
models for unsolved structures for mouse and rat ERα-LBD.  
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Using known ERα agonists and a homologous series of paraben compounds, our in silico 
models of ERα-LBD produced molecular docking data that recognized both potent and weak ER 
agonists. These in silico models were also able to produce docking results that were used to sort 
the test compounds according to their predicted affinity for ERα, which agreed with their 
reported in vitro potencies towards ERα. Additionally, our novel application of the Sorenson 
similarity index suggested that these same ER agonists were predicted to make similar ligand-
receptor residue contacts in both human and rodent ERα-LBDs. These findings not only validate 
the use of rodent models as a tissue source for identify estrogenic EDCs, but they also highlight 
the effectiveness of an in silico approach to characterize compounds for their predicted affinity 
towards ERα. 
The use of in silico models, such as the ones reported here, demonstrate the potential to 
be applied in the development of safer and less estrogenic paraben compounds commonly used 
in the manufacture of consumer goods. For example, Bergquist et al. recently reported that 3,5-
disubstituion of nBuP and octylparaben can simultaneously increase the antimicrobial potency of 
parabens while decreasing their affinity towards ERα [17]. To test the utility of our in silico 
models beyond our initial series of test ligands, we conducted additional docking studies with 15 
3,5-disubstituted paraben compounds and compared their predicted affinity towards ERα with 
their in vitro potencies presented by Bergquist et al. The use of ligand efficiency metrics allowed 
us to directly compare the relative strength of ligand-receptor interactions between the Bergquist 
et al. in vitro data with our in silico docking results. Strikingly, we found a high correlation 
between the ligand efficiency data between the Bergquist et al experimental data and our in 
silico molecular docking results. These data suggest that our in silico models were not only 
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effective in predicting the relative affinity 3,5-disubstituted paraben compounds, but our models 
demonstrate the potential to applied in design of potentially safer preservative compounds. 
In contrast to EDCs, the detection of commonly reoccurring ESR1 LBD somatic 
mutations found in metastatic breast cancer patients may serve as another explanation for the 
issue of recurrence observed in ER-positive breast cancer. It has been reported that these LBD 
mutations are frequently detected in 30-40% of patients with advanced disease who have become 
resistant to endocrine therapy [18]. In vitro characterization has shown that cells expressing these 
LBD mutations appear to confer a drug resistant phenotype to compounds commonly used in the 
adjuvant setting to treat ER-positive breast cancer [19, 20]. This drug resistant phenotype is 
especially problematic for patients with advanced disease who are often treated with the selective 
estrogen receptor degrader (SERD) Fulvestrant. Currently, the effectiveness of Fulvestrant is 
limited to due to poor bioavailability and that it must be administered intramuscularly. Therefore, 
the presence of LBD mutations necessitates the development of orally bioavailable and potent 
SERDs to inhibit ER-dependent tumor cell proliferation. Fortunately, significant progress in 
synthetic chemistry has led to improvements in the Proteolysis Targeting Chimera (PROTAC) 
method to induce targeted degradation of specific proteins or receptors [21]. The PROTAC 
method works by allowing for the development of bifunctional small molecules designed to 
target and degrade proteins by hijacking the ubiquitin-proteasome pathway. 
Thus, we tested the hypothesis that novel agents designed with the PROTAC method 
could achieve superior degradation of ERα as compared to current compounds used in endocrine 
therapy. We found that PROTAC degrader ERD-148 was able to achieve superior 
downregulation of ERα as compared to Fulvestrant in WT and mutant cells expressing LBD 
mutations. Overall, we have provided evidence which suggests ERD-148 inhibits the 
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proliferative ability of ER-dependent breast cancer cells by downregulating ERα and suppressing 
ER-dependent gene activation. Although ERD-148 has been designed to be an oral SERD, 
animal models are needed to establish the therapeutic potential of this compound relative to 
Fulvestrant or similar ERα degraders. Furthermore, additional studies are needed to develop 
more potent iterations of ERD-148 and evaluate their therapeutic potential for use in clinical 
trials of metastatic ER-positive breast cancer patients. Patients with advanced breast cancer, as 
well as those harboring ESR1 mutations, would likely benefit the most from treatments with a 
compound like ERD-148 if it is shown to be more effective than Fulvestrant in in vivo models. 
However, a thorough toxicological profile for ERD-148 and safety assessment is needed prior to 
its use in clinical trials.   
In summary, the findings presented in this dissertation have shown that: 1) human 
metabolites of nBuP and iBuP exhibit weak estrogenic behavior and should be considered as 
equally important components of total environmental exposure from paraben compounds; 2) in 
silico mutagenesis of a template receptor with high sequence similarity is an effective approach 
to model unknown receptors which also has substantial utility in manufacturing or drug 
development applications when comparing ligand-receptor interactions; and 3) inhibiting ER-
dependent cell proliferation in breast cancer with novel agents designed via the PROTAC 
method demonstrate potential for effective treatment of patients with acquired resistance to 
endocrine therapy (Figure 5.1). Overall, these findings contribute to our understanding of EDCs 
that may be associated with breast cancer recurrence and highlights the utility of in silico models 
in identifying estrogen mimics prior to conducting and in vitro or in vivo study. We have also 
shown that novel agents designed with the PROTAC method could be used to develop more 
effective SERDs used in to treat patients with advanced breast cancer. Future studies will be 
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needed to determine whether exposure to estrogenic EDCs or the presence of ESR1 mutations 
contribute to a greater risk of recurrence or poorer clinical outcomes specifically among patients 
with advanced disease.   
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Figure 5.1. Conceptual Model of the role suspected of estrogen mimics and acquired 
resistance in ER-positive breast cancer. Paraben metabolites, 2OH and 3OH, bind to ERα and 
promote an increase in ER-dependent gene expression and cell proliferation. In silico 
experiments supported literature data regarding the use of 3,5-substitution to decrease the 
predicted binding affinity of n-butylparaben towards ERα. Similar suspected estrogen mimics 
can be prescreened with in silico models of human and rodent ERα-LBD with relatively high 
confidence. Targeted degradation of ESR1 mutants inhibits ERα signaling and cell proliferation 
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Evaluating the Association between Biomarkers of Parabens and Phenol Exposure and 
Recurrence in ER-Positive Breast Cancer Patients 
Introduction 
 
Breast cancer is currently the most commonly diagnosed malignancy among women in the 
United States (US) with an estimated 266,000 new diagnoses and 41,000 deaths in 2018 alone 
[1]. The ability of estrogen to induce breast cancer cellular proliferation is concerning because it 
is estimated that approximately 70% of all diagnosed breast cancers express the estrogen 
receptor (ER) and are deemed ER-positive [2]. Pharmacological approaches have been 
developed to block ER signaling using ER antagonists such as tamoxifen, and more recently 
aromatase inhibitors (AIs), which inhibit the synthesis of estrogens [3], have been used. 
Postmenopausal women with ER-positive breast cancer are typically given AIs in the adjuvant 
setting to inhibit the synthesis of estrogens produced in the peripheral tissues and adrenal glands 
[4]. This pharmacological approach works mechanistically by blocking the action of CYP19 
aromatase which minimizes the stimulation of estrogen dependent breast tumors from 
endogenous estrogens [5]. Nevertheless, many women still experience disease recurrence for 
unknown reasons despite evidence of improvement in disease-free survival rates among 
postmenopausal women taking AIs with ER-positive breast cancer [6, 7]. For example, after five 
years of endocrine therapy, the recurrence rate among postmenopausal women with ER-positive 
breast cancer has been reported to continuously increase ~1-2% every year among those who 
have not recurred [7-9]. More recently, a meta-analysis of 88 clinical trials showed that the rate 
 176 
of recurrence still increases ~1-2% every year for at least 20 years post treatment among ER-
positive patients even when adjusting for several tumor characteristics [10]. It has been 
suggested that non-classical estrogens resulting from androgen metabolism could contribute as 
potential mechanism of AI resistance and as a potential explanation for recurrence in ER-positive 
patients [5]. Alternatively, resistance to antiestrogen therapy for patients on AIs could also be 
attributed to exposure from environmental estrogen mimicking chemicals, or xenoestrogens [5, 
11]. 
Recently, there has been increasing public awareness and research into environmental 
chemicals that may have biologically relevant, endocrine disrupting properties [12]. 
Xenoestrogens include many of these suspected endocrine disrupting compounds that have 
previously been shown to display agonistic behavior toward estrogen receptor-α (ERα) in vitro 
[13, 14]. Parabens are one class of xenoestrogen that have been investigated for whether current 
human exposure levels are a cause for concern [15]. Given their antimicrobial properties, 
parabens are frequently used as a preservative in numerous pharmaceuticals, food products, and 
personal care products [16, 17]. One report has measured five different paraben compounds in 
breast mastectomy samples taken from patients with ER+PR+ primary tumors where it was 
shown that 27% of breast tissue samples contained at least one measurable paraben compound 
that was above its lowest-observed-effect concentration as determined in ER-positive MCF-7 
cells [18]. The same report also showed that representative concentrations of paraben compounds 
measured in breast tissue could promote cellular proliferation of ER-positive MCF-7 cells in 
combination whereas many these same compounds could not do so when tested alone [18]. 
Due to ubiquitous exposure of the public to xenoestrogens like parabens, it is possible 
that exposure to these compounds could explain part of the reason why adjuvant chemotherapy 
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can fail certain breast cancer patients taking drugs such as aromatase inhibitors. Although AIs 
have been proven to be effective in treating ER-positive breast cancer, their inherent design and 
mechanism of action cannot inhibit the weak agonist behavior from exposure to environmental 
sources of estrogen mimicking compounds, or xenoestrogens. Postmenopausal women taking 
AIs with ER-positive breast cancer could be susceptible to further disease progression and 
recurrence due to their individual exposure level of xenoestrogens such as parabens. It is possible 
that the combined exposure of parabens and some of their metabolites may be a contributing 
factor for disease recurrence in ER-positive breast cancer patients on anti-estrogen therapy, such 
as AIs. 
Despite evidence demonstrating the presence of parabens in several human tissues, there 
is still significant debate over their current risk to the general population [15]. To provide insight 
into whether weak ERα agonists like parabens may contribute to a greater risk for recurrence 
among ER-positive patients on anti-estrogen therapy, we conducted a pilot study comparing 
urinary paraben and phenol exposure between non-metastatic, ER-positive patients currently on 
anti-estrogen therapy with samples from metastatic ER-positive patients the moment disease 
progression was determined. Our hypothesis is that ER-positive breast cancer patients who have 
recurred will have significantly higher levels of paraben or phenol exposure compared to breast 
cancer patients who have not recurred. The concentration of several parabens and phenols was 
determined in these samples and we evaluated whether there was an association between urinary 
paraben and phenol exposure with breast cancer progression.  
 
Materials and Methods 
Study participants 
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All participants were patients with a diagnosis of ER-positive and HER2-negative 
(ER+/HER2-) breast cancer after 2005 who were enrolled into an ongoing prospective study at 
the University of Michigan Cancer Center. All participants were given informed consent and 
urine samples were de-identified prior to analysis.  Cohort 1 consisted of patients (n=20) with 
stage II or III hormone receptor positive breast cancer (ER+ and/or PR > 1%) and HER2-
negative tumor type who were diagnosed after 2005 who are at a high-risk for recurrence, have 
completed surgery, chemotherapy, radiation therapy, and show no indication of disease 
recurrence while on anti-estrogen therapy for at least 2-3 years. Patients in cohort 1 who 
progressed to metastatic disease since enrollment or had another systemic malignancy within the 
previous five years of recruitment were excluded from analysis. Participants in cohort 1 were 
asked to provide a baseline urine sample at the time of enrollment. Each patient in cohort 1 was 
repeatedly followed up with in 2-3 month intervals for a maximum of 36 months to determine 
whether there was evidence of tumor progression. Cohort 2 consisted of patients (n=11) who 
were diagnosed with ER+/HER2- metastatic breast cancer with high disease burden who have 
documented disease progression. Patients in cohort 2 who were diagnosed with another active 
systemic malignancy within the last five years were excluded. Urine samples were collected 
from patients in cohort 2 at the time progression was determined by their medical oncologist. 
 
Urinary paraben and phenol measurement 
All urine samples were collected and aliquoted into 1.5 mL Eppendorf tubes with EDTA 
preservative solution and stored at –80 °C until analysis by NSF International (Ann Arbor, MI). 
Twelve phenols and parabens, comprising bisphenol-A (BPA), bisphenol-S (BPS), bisphenol-F 
(BPF), benzophenone-3 (BP3), triclosan (TCS), triclocarban (TCC), 2,4-dichlorophenol (2,4-
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DCP), 2,5-dichlorophenol (2,5-DCP), n-butylparaben (BuP), ethylparaben (EP), methylparaben 
(MP), and propylparaben (PrP), were measured in urine at NSF International (Ann Arbor, MI) 
using isotope dilution–liquid chromatography–tandem mass spectrometry (ID–LC–MS/MS) as 
described previously [19]. Sample concentrations with a zero value were substituted with the 
second lowest concentration measured for that analyte. Urinary creatinine was measured at the 
Michigan Diabetes Research Center (MDRC) (Ann Arbor, MI) on a Randox RX Series Daytona 
chemistry analyzer. The instrument was calibrated using 0.9% NaCl as zero calibrator, Randox 
Calibration Serum Level 2, and Randox Calibration Serum Level 3. The Randox Calibration 
Serum Level 2 and 3 are traceable to creatinine reference materials NIST 909b and NIST 967. 
Cliniqa Bi-Level Liquid QC Urine Chemistry Controls are also analyzed with each run for 
quality control. The Intra assay precision (%CV) was determined at three levels (n=88):  2.1% 
(51 mg/dL), 2.1% (102 mg/dL), and 1.5% (203 mg/dL). The Inter assay precision (%CV) was 
determined at three levels (n=88): 3.0% (51 mg/dL), 3.0% (102 mg/dL), and 2.8% (203 mg/dL).  
 
Data Analysis 
All models were adjusted for with available demographic or tumor characteristics. 
Covariates that were considered included: recurrence status (binary), creatinine concentration 
(continuous, mg/dL); age (continuous, years); and body mass index (BMI, kg/m2). Multiple 
linear regression models were fit using the following format: Concentration ∼Recurrence Status 
+ Age + BMI. For all models, the concentration outcome variable was defined as log (analyte 
concentration). A total of 31 participants were included in final regression analyses. Statistical 





Population characteristics and exposure 
Available demographic and tumor characteristics of the breast cancer patients in the pilot study 
are presented in Table A1. The average age for all patients was 58 years, all determined to be 
ER+HER2-, most determined to be node positive (90%), and identifying as white or Caucasian 
(94%). A total of 31 urine samples were analyzed for twelve different parabens and phenols as 
described in the Methods. Concentrations of each paraben or phenol measured from urine 
samples are shown as per g of urinary creatinine with the medians and means for each compound 
displayed in Table A2. BPS was not detectable in any of the urine samples analyzed. TCC 
concentrations were found to be below the LOD for all analyzed samples. Parabens and phenols 
that were detected in less than 80% of samples included BPF (29% detection), TCS (48% 
detection), EP (48% detection), and BuP (29% detection) as summarized in Table A2.  
 
Paraben phenol exposure and breast cancer progression 
Patients with clinically determined disease progression were observed with 3 to 6 fold 
higher, but non-significant, BPA median and mean concentrations respectively as compared to 
non-progressing patients after adjusting for urinary creatinine, age, and BMI (p = 0.498) (Table 
A3). Patients who were progressing were also found to have significantly lower urinary BP3 
concentrations than the non-progressing group after adjusting for urinary creatinine only (Table 
A3). Disease progression was not determined to show a meaningful statistical association with 
any of the other urinary parabens or phenols listed in Table A3.     
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Discussion 
Exposure from suspected endocrine disrupting compounds, such as phthalates [20] and 
polychlorinated biphenyls (PCBs) [21, 22], have been associated with an increased risk for breast 
cancer with limited reports examining the same relationship for paraben compounds. 
Additionally, paraben exposure has not been reported in the context of breast cancer recurrence 
whereas exposure to PCB118 and total PCB exposure, measured in adipose tissue, have 
previously been shown to be associated with an increased risk for recurrence [23]. To examine 
the potential association between paraben exposure and breast cancer recurrence, we measured 
the concentration of several parabens and phenols in banked urine samples from non-metastatic 
breast cancer patients and samples from metastatic patients at time disease progression was 
determined. Several of the analytes measured were determined to show concentration ranges that 
were fairly consistent with prior publications with the exception of BPA being nearly 10 to 100 
fold higher than female non-cancer patients [19, 24]. However, multiple linear regression 
analysis did not produce any meaningful statistical associations for any of the parabens or 
phenols included in urine analysis. BPA median urine concentrations were found to be several 
fold higher in patients with disease progression but this observation was still not found to be 
significant after adjusting for urinary creatinine, age, and BMI.  
 There are several limitations and issues with the original urine sample collection which 
likely explain the non-statistically significant associations found in this pilot study as well as 
why many samples were determined to be below the LOD. Since these banked urine samples 
were initially collected for a separate ongoing clinical study with alternative biomarkers of 
interest, we did not have control over how these urine samples were collected where the urine 
was stored in large volumes of EDTA upon collection. Furthermore, logistical issues prevented 
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onsite adjustment in the EDTA to urine volume ratio during sample collection which prevented 
us from knowing the exact dilution for each sample and subsequent non-uniform EDTA to urine 
ratios across all the samples analyzed. This processing step ultimately resulted in highly dilute 
samples among the metastatic patients and with generally more analyte measurements with 
concentrations below the LOD relative to the non-metastatic patients. Another unavoidable 
factor was that these samples underwent several freeze-thaw cycles by the time urine 
concentrations were determined and likely explain why BPS could not be detected in any of the 
provided samples. Of the four paraben compounds measured, EP and BuP were detected less 
frequently in our samples which is consistent with prior publications [25] but the EDTA dilution 
may be a greater contributing factor as to why many of these measurements were found to be 
below the LOD. Parabens are also known to be metabolized and excreted within several hours 
[26] and may be subject to temporal variability [27, 28] which could not be accounted for during 
initial urine collection.    
Due to the density of EDTA and the large volume of it used in the sample collection, we 
could not measure the specific gravity of our samples for normalization. Therefore, we had to 
rely on urinary creatinine as a means to standardize our samples before determining any 
statistical association. For the statistical analysis, we only had access to limited demographic 
information about each of the enrolled patients which hampers our ability to adjust for other 
variables such as income, level of education, socioeconomic status or similar characteristics 
during the analysis stage. Given the issue of several measurements being below the LOD for 
some of our analytes and the limited number of samples from patients with the outcome of 
disease progression, it is difficult to make meaningful conclusions about this data set. However, 
the observation of BPA exposure being several fold higher in the patients with progression is a 
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phenomenon worth exploring in a larger prospective study that is not underpowered which is the 





Table A1. Population characteristics of ER+/HER2- breast cancer patients in study. 
Characteristic   All Non-metastatic Metastatic Progressions 
Number    31 20  11 
Age at enrollment (years)     
 [mean ± SD 
(range)] 
57.5 ± 10.1 (40-85) 
54.0 ± 10.4 (40-85)  
64.1 ± 5.2 (55-
75) 
Race [n(%)]       
 White or Caucasian 29 (93.5) 18 (90)  11 (100) 
   Asian   1(3.2) 1(5)  0 (0) 
 Missing   1(3.2) 1 (5)  0 (0) 
BMI [mean ± SD (range)]  
28.4 ± 7.7 (15.8-
48.3) 
29.1 ± 8.4 (18.5-
48.3) 
27.1 ± 6.3 (15.8-37.1) 
ER+/HER2- 
[n(%)] 
  31 (100) 20 (100)  11 (100) 
Tumor size [n(%)]       
 ≤ 2 cm   8 (25.8) 5 (25)  3 (27.2) 
 ≥ 2 cm   20 (64.5) 15 (75)  5 (45.5) 
 Missing   3 (9.6) 0 (0)  3 (27.2) 
Axillary nodal status [n(%)]     
 Node positive  28 (90.3) 20 (100)  8 (72.7) 
 Node negative  1 (3.2) 0 (0)  1 (9.1) 










































Mean SEM Median 
% ≥ 
LOD 
Mean SEM Median 
BPA 0.4 94 100 152.36 32.99 124.03 82 971.89 576.22 467.79 
BPF 0.4 29 30 0.80 0.09 0.72 27 3.38 1.81 1.28 
BP3 0.4 84 100 85.02 63.51 4.57 55 5.52 1.42 3.84 
TCS 2.0 48 60 25.02 12.28 3.96 27 46.91 43.98 2.60 
TCC 2.0 0 0 0.24 0.04 0.16 0 0.55 0.12 0.43 
24-DCP 0.2 81 90 0.70 0.08 0.64 64 1.62 0.50 0.74 
25-DCP 0.2 87 90 1.20 0.23 0.97 82 1.75 0.43 1.22 
MP 1.0 100 100 248.47 85.75 125.09 100 85.20 23.23 51.80 
EP 1.0 48 65 100.37 37.17 4.64 18 21.25 13.86 1.36 
PrP 0.2 100 100 48.08 16.44 13.59 100 25.73 10.86 9.85 




















Table A3. Associations between urinary paraben or phenol concentrations of ER+/HER2- breast cancer patients and progression status. 







Log(Phenol)=Status+ log(CR)+ Age 
Model 4: 
Log(Phenol)=Status+ log(CR)+ Age+ 
BMI 
Compound ß 95% CI p-value ß 95% CI p-value ß 95% CI p-value ß 95% CI p-value 
MP -0.606 -1.123, -0.083 0.025 -0.188 -0.730, 0.353 0.482 -0.116 -0.736, 0.503 0.704 -0.115 -0.749, 0.518 0.711 
PrP -0.462 -1.107, 0.184 0.154 -0.054 -0.764, 0.654 0.876 0.068 -0.741, 0.877 0.865 0.060 -0.762, 0.881 0.882 
BPA -0.017 -0.848, 0.816 0.969 0.082 -0.909, 1.073 0.866 0.381 -0.729, 1.492 0.487 0.379 -0.755, 1.513 0.498 
25-DCP -0.181 -0.389, 0.026 0.084 -0.052 -0.280, 0.176 0.647 -0.129 -0.383, 0.125 0.306 -0.129 -0.388, 0.130 0.317 
24-DCP -0.135 -0.308, 0.038 0.121 -0.067 -0.267, 0.133 0.497 -0.049 -0.278, 0.181 0.666 -0.053 -0.283, 0.176 0.642 
BP3 -0.799 -1.361, -0.237 0.007 -0.734 -1.403, -0.064 0.033 -0.514 -1.261, 0.233 0.170 -0.512 -1.275, 0.250 0.179 
BPF 0.036 -0.230, 0.303 0.782 0.235 -0.048, 0.517 0.100 0.222 -0.103, 0.546 0.172 0.225 -0.104, 0.554 0.171 
BuP -0.243 -0.620, 0.135 0.199 -0.092 -0.529, 0.344 0.667 -0.174 -0.671, 0.324 0.480 -0.184 -0.679, 0.311 0.451 
EP -0.925 -1.743, -0.107 0.028 -0.709 -1.673, 0.255 0.143  -0.659 -1.767, 0.449 0.233 -0.669 -1.795, 0.457 0.233 
TCS -0.524 -1.093, 0.045 0.070 -0.171 -0.798, 0.456 0.580 -0.063 -0.778, 0.652 0.859 -0.072 -0.795, 0.650 0.838 
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